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A B S T R A C T
Background
Sickle cell disease is an autosomal recessive inherited haemoglobinopathy which causes painful vaso-occlusive crises due to sickle red
blood cell dehydration. Vaso-occlusive crises are common painful events responsible for a variety of clinical complications; overall
mortality is increased and life expectancy decreased compared to the general population. Experimental studies suggest that intravenous
magnesium has proven to be well-tolerated in individuals hospitalised for the immediate relief of acute (sudden onset) painful crisis and
has the potential to decrease the length of hospital stay. Some in vitro studies and open studies of long-term oral magnesium showed
promising effect on pain relief but failed to show its efficacy. The studies show that oral magnesium therapy may prevent sickle red
blood cell dehydration and prevent recurrent painful episodes. There is a need to access evidence for the impact of oral and intravenous
magnesium effect on frequency of pain, length of hospital stay and quality of life.
Objectives
To evaluate the effects of short-term intravenous magnesium on the length of hospital stay and quality of life in children and adults
with sickle cell disease. To determine the effects of long-term oral magnesium therapy on the frequency of painful crises and the quality
of life in children and adults with sickle cell disease.
Search methods
We searched the Cochrane Haemoglobinopathies Trials Register, compiled from electronic database searches and handsearching of
journals and conference abstract books.
Date of last search of the Cochrane Cystic Fibrosis and Genetic Disorders Group’s Haemoglobinopathies Trials Register: 01 December
2016.
Date of last search of other resources (clinical trials registries): 29 March 2017.
Selection criteria
We searched for published and unpublished randomized controlled studies of oral or intravenous magnesium compared to placebo or
no magnesium.
Data collection and analysis
Authors independently assessed the study quality and extracted the data using standard Cochrane methodologies.
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Main results
We included five randomized placebo-controlled studies with a total of 386 participants (aged three to 53 years). Two shorter parallel
studies (n = 306) compared intravenous magnesium sulphate to placebo (normal saline) for admission to hospital due to a vaso-occlusive
crisis, for which we were able to analyse data. The quality of evidence was moderate for studies presenting this comparison mainly due
to limitations due to risk of bias and imprecision. Two of the three longer-term studies comparing oral magnesium pidolate to placebo
had a cross-over design. The third was a parallel factorial study which compared hydroxyurea and oral magnesium to each other and
to placebo over a longer period of time; we only present the comparison of oral magnesium to placebo from this study. The quality of
evidence was very low with uncertainty of the estimation.
The eight-hourly dose levels in the two studies of intravenous magnesium were different; one used 100 mg/kg while the second used 40
mg/kg. Only one of these studies (n = 104) reported the mean daily pain score while hospitalised (a non-significant difference between
groups, moderate quality evidence). The second study (n = 202) reported a number of child- and parent-reported quality of life scores.
None of the scores showed any difference between treatment groups (low quality evidence). Data from one study (n = 106) showed no
difference in length of stay in hospital between groups (low quality evidence). Both studies reported on adverse events, but not defined
by severity as we had planned. One study showed significantly more participants receiving intravenous magnesium experienced warmth
at infusion site compared to placebo; there were no differences between groups for other adverse events (low quality evidence).
Three studies (n = 80) compared oral magnesium pidolate to placebo. None of them reported data which we were able to analyse. One
study (n = 24) reported on the number of painful days and stated there was no difference between two groups (low quality evidence).
None of the studies reported on quality of life or length of hospital stay. Two studies (n = 68) reported there were no differences in
levels of magnesium in either plasma or red blood cells (moderate quality evidence). Two studies (n = 56) reported adverse events. One
reported episodes of mild diarrhoea and headache, all of which resolved without stopping treatment. The second study reported adverse
events as gastrointestinal disorders, headache or migraine, upper respiratory infections and rash; which were all evenly distributed across
treatment groups (moderate quality evidence).
Authors’ conclusions
Moderate to low quality evidence showed neither intravenous magnesium and oral magnesium therapy has an effect on reducing
painful crisis, length of hospital stay and changing quality of life in treating sickle cell disease. Therefore, no definitive conclusions can
be made regarding its clinical benefit. Further randomized controlled studies, perhaps multicentre, are necessary to establish whether
intravenous and oral magnesium therapies have any effect on improving the health of people with sickle cell disease.
P L A I N L A N G U A G E S U M M A R Y
Magnesium for treating sickle cell disease
Review question
We reviewed the evidence of the effect of intravenous (given into a vein) magnesium and oral (taken by mouth) magnesium on the
frequency of painful crises (sickle cell crises with severe pain due to blockages of the blood supply to bones, joints, lungs, liver, spleen,
kidney, eye or central nervous system), length of hospital stay and quality of life in people with different types of sickle cell disease.
Background
Sickle cell disease is a relatively common inherited blood disease. Its symptoms include the rapid onset of painful crises, which can
lead to increased rates of hospital admission. The likely cause is that deformed sickle-shaped red blood cells put stress on blood vessels
which blocks them and leads to vaso-occlusive crises. Vascular function is impaired in people with sickle cell disease. It is known that
magnesium can widen blood vessels and, when regularly administered, it improves the amount of liquid in red blood cells and can
help stop their shape deforming. Intravenous magnesium can cause mild to moderate side effects after administration e.g. nausea,
vomiting, feeling of warmth, low blood pressure, etc.; and oral magnesium supplementation can cause mild side effects e.g. diarrhoea
and abdominal cramps. We wanted to find out whether short-term intravenous magnesium and long-term oral magnesium is better
than a placebo (dummy treatment with no magnesium) or no magnesium treatment, for reducing painful crises, shortening the length
of stay in hospital and for improving quality of life. We were also interested in side effects of treatment with magnesium and some
blood tests.
Search date
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The evidence is current to: 01 December 2016.
Study characteristics
The review included five studies with a total of 386 people with sickle cell disease aged between four and 53 years. Two studies (306
people) compared intravenous magnesium to a placebo (in this case saline (salty water)) in people admitted to hospital as an emergency
because of pain and lasted until they were discharged (less than four weeks). Two of the three longer-term studies compared oral
magnesium pidolate with placebo and the third study compared hydroxyurea and magnesium pidolate to each other and to placebo
but we have only included the results of the comparison of magnesium pidolate to placebo).
Key results
Not all the studies reported on our outcomes and we could not analyse data from most of the studies. We did find that in the people
admitted to hospital as emergency cases, intravenous magnesium did not reduce pain levels, could not shorten the length of time spent
in hospital and did not improve their quality of life compared to placebo. However, more people given magnesium experienced warmth
where the needle was inserted than those people who were given placebo.
Oral magnesium pidolate, given over a longer period, did not reduce the severity of painful episodes and had no measurable effect on
properties of sickled red cells (e.g. magnesium levels in the blood). Oral magnesium appeared to be safe and well-tolerated with only
mild side effects (diarrhoea and headache). Further research is needed to compare the short-term and long-term benefits of magnesium
treatment and its side effects.
Quality of the evidence
The quality of evidence for intravenous magnesium and oral magnesium in treating sickle cell disease was moderate for pain when using
short-term intravenous magnesium and for levels of magnesium in the blood when taking longer-term oral magnesium supplements.
The quality of evidence was low for all other outcomes we measured. All of the included studies of oral or intravenous magnesium for
treating sickle cell disease had some aspects that could undermine the reliability of their results. Therefore, we have some uncertainty
of these findings and further research may provide evidence that could change our conclusions.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Intravenous magnesium sulphate versus placebo for treating sickle cell disease
Patient or population: people with sickle cell disease
Settings: emergency department (Toronto, Canada); children’s hospital (USA)
Intervention: intravenous magnesium sulphate
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Intravenous magne-
sium sulphate
Change in frequency of
vaso-occlusive painful
crises
(as measured by pain
diary of days with sig-
nificant pain)
Follow up: Not reported
The mean pain score in
placebo group was 5.3 .
The mean pain score in
the intervent ion group
was 0.10 higher (0.82
lower to 1.02 higher)
than in the placebo
group.
NA4 104
(1 study)
⊕⊕⊕©
moderate1
There was no signif i-
cant dif f erence in the
mean pain score be-
tween the intervent ion
group and the placebo
group
HRQoL score (Child- re-
ported PedsQL generic
scale) at 1 week follow
up
Follow up: 7-10 days
and 3 months af ter dis-
charge f rom hospital
NA4 The mean HRQoL score
(child-reported HRQoL)
in the intervent ion
group was
2.3 lower (7.21 lower to
2.61 higher) than in the
placebo group.
NA4 202
(1 study)
⊕⊕©©
low2,3
There was no signif i-
cant dif f erence in the
mean HRQoL score be-
tween the intervent ion
group and the placebo
group
HRQoL score (Child-
reported PedsQL mul-
tidimensional fatigue
scale) at 1 week follow
up
Follow up: 7-10 days
NA4 The mean HRQoL score
(child-reported HRQoL)
in the intervent ion
group was 1.4 lower
(13.44 lower to 10.
64 higher) than in the
NA4 202
(1 study)
⊕⊕©©
low2,3
There was no signif i-
cant dif f erence in the
mean HRQoL score be-
tween the intervent ion
group and the placebo
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and 3 months af ter dis-
charge f rom hospital
placebo group. group
HRQoL score (Child- re-
ported PedsQL sickle
cell disease module) at
1 week follow up
Follow up: 7-10 days
and 3 months af ter dis-
charge f rom hospital
NA4 The mean HRQoL score
(child-reported HRQoL)
in the intervent ion
group was 3.5lower
(14.95 lower to 7.95
higher) than in the
placebo group.
NA4 202
(1 study)
⊕⊕©©
low2,3
There was no signif i-
cant dif f erence in the
mean HRQoL score be-
tween the intervent ion
group and the placebo
group
Length of hospital stay
(hours)
Follow up: Not reported
The mean length of hos-
pital stay in the control
group was 117.9 hours.
The mean length of hos-
pital stay in the inter-
vent ion group was 14.
7 higher (20.51 lower
to 49.91 higher) than in
the placebo group.
NA4 104
(1 study)
⊕⊕©©
low1,2
There was no signif i-
cant dif f erence in the
mean length of hospital
stay between the inter-
vent ion group and the
placebo group
Adverse effects: hy-
potension
Follow up: Not reported
5 out of 151 part ici-
pants.
2 out of 155 part ici-
pants.
RR 2.57
(0.50 to 13.08)
306
(2 studies)
⊕⊕©©
low1,2
There was no signif i-
cant dif f erence in hy-
potension between the
intervent ion group and
the placebo group
Adverse effects:
warmth at infusion site
Follow up: 7-10 days
and 3 months af ter dis-
charge f rom hospital
2 out of 102 part ici-
pants.
26 out of 100 part ici-
pants.
RR 13.26
(3.23 to 54.40)
202
(1 study)
⊕⊕©©
low2,3
There was signif icant
dif f erence in warmth at
the infusion site be-
tween the intervent ion
group and the placebo
group
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; HRQoL: health-related quality of lif e; NA: not applicable; RR: risk rat io.
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GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1 Evidence downgraded due to serious lim itat ion of risk of bias: the study lacked blinding of outcome assessment and the
targeted sample size expected f rom protocol was not achieved.
2 Evidence downgraded to imprecision: wide 95% CIs of the ef fects of outcomes of the intervent ion.
3 Serious risk of bias: method of blinding of outcome assessment was not clearly described. Downgraded by one level f rom
high.
4 The results f rom the study were presented as either median or mean dif ference so an est imate of risk within the control
group is not available.
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B A C K G R O U N D
Description of the condition
Sickle cell disease (SCD) is a hereditary red cell disorder found in
populations across the world (Weatherall 2001). It is caused by a
single point mutation in codon 6 of the human beta-globin (β-
globin) gene that results in the substitution of valine for glutamic
acid and the synthesis of pathological haemoglobin S (HbS). Peo-
ple with SCD can be homozygous for the pathological haemoglo-
bin S(SS) or heterozygous with co-inherited other haemoglobin
disorders such asHbC (SC) or β-thalassaemia (Sβ) (Mehta 2000).
The worldwide distribution of SCD has dramatically changed in
recent decades due to the survival of people with SCD in endemic
areas, such as sub-Saharan countries, and the migration of pop-
ulations from endemic areas to some western countries (Modell
2008; Weatherall 2001). The condition is characterized by de-
creased life expectancy targeting both paediatric and adult popu-
lations (Hamideh 2013; Platt 1994). Several years ago, the mean
survival rate was 14.3 years for children with SCD (Diggs 1973),
but this increased up to 20 years of age in children and adoles-
cents as reported in a co-operative study of SCD (Leikin 1989).
In adults with SCD life expectancy is 48 years for females and 42
years for males (Platt 1994). Mortality rates are low in children
with SCD in developed countries (0.5 to 1.0 per 100,000 popu-
lation) and high in some selected developing countries (15.5 per
1000 children) (Rahimy 2009).
In SCD, pathophysiological studies have shown that the dense,
dehydrated red cells play a central role in acute and chronic clinical
manifestations of SCD, in which production of sickle-shaped red
blood cells in capillaries and small vessels leads to obstruction of
the microcirculation by sickled red blood cells, causing ischemias
(Belcher 2014; De Franceschi 2011; Hebbel 2011; Solovey 2001;
Vinchi 2013). However, the persistent membrane damage with
loss of deformability and changes in cell morphology (HbS poly-
merization) also favours the generation of distorted rigid cells and
further contributes to vaso-occlusive events and cell destruction in
the peripheral circulation (De Franceschi 2011; Kuypers 1998).
Studies in both mouse models and humans with SCD have shown
that vaso-occlusive crises (VOCs) result from a complex (and still
only partially known) scenario, which also involves neutrophils,
natural killerT-cells (NKTcells) (DeFranceschi 2011; Field 2013)
and platelets (Ataga 2003; Klings 2001; Okpala 2004), as well as
soluble factors such as cytokines or the coagulation system (De
Franceschi 2011; Sabaa 2008). In SCD, recurrent VOCs pro-
mote tissue damage, characterized by chronic inflammation and is-
chaemia-reperfusion cellular injury (where ischaemia means a lack
of oxygen) that leads to acute and chronic multi-organ dysfunc-
tion (Reiter 2003). In young children, themain clinical manifesta-
tions of VOCs are dactylitis, osteomyelitis, osteonecrosis, splenic
infarct, splenic sequestration, acute chest syndrome, stroke, pap-
illary necrosis leading to kidney failure (Yaster 2000). In young
adults with SCD the most frequent causes of hospitalizations are
pain crisis, pneumonia, sepsis, acute chest syndrome and heart
failure (Brousseau 2010; Caroll 2009; Platt 2000).
Recent evidence on the presence of circulating free heme and hae-
moglobin, related to the saturation of the physiological binding
system, such as haptoglobin and haemopexin (De Caterina 1995;
Lane 1996; Vinchi 2013) has opened an interesting prospective on
the intravascular pro-oxidant environment and the local reduction
of nitric oxide, which avidly binds free Hb promoting regional
relative nitric oxide deficiency (De Franceschi 2003; Kato 2008;
Rees 2010; Siciliano 2011). Thus, the two main clinical manifes-
tations of SCD are acute VOCs and chronic haemolytic anaemia.
The clinical manifestations of SCD are related to the peculiar
biochemical properties of HbS, which polymerises when deoxy-
genated. Sickling of red blood cells has been shown to be expo-
nentially related to the haemoglobin concentration. This demon-
strates a crucial role of HbS concentration in sickling. Cyclic poly-
merization-depolymerization ofHbS is paralleled by the abnormal
activation of red cell membrane cation systems resulting in a re-
duction of cell ion and water content (cell dehydration), increased
red cell density and further acceleration of HbS polymerizations
(Brugnara 1993a;DeFranceschi 1994;McNaughton-Smith2008;
Stocker 2003). Dense, dehydrated erythrocytes are likely to un-
dergo instant polymerizations in conditions ofmild hypoxia due to
their high HbS concentration, and HbS polymers may be formed
under normal oxygen pressure.
Analysis of membrane physiology of sickled red cells have shown
abnormalities in different specialized membrane-embedded trans-
porters that carry cations, anions and water across the erythro-
cyte membrane. In the last two decades, studies on the nature
and properties of the pathways mediating potassium (K+) loss in
sickle cell erythrocytes have identified three major membrane sys-
tems; the Ca2+-activated K+ channel, known as the Gardos chan-
nel (Brugnara 1993a; De Franceschi 1994; De Franceschi 1996;
Vandorpe 1998), operating in parallel with the conductive Cl−
pathway (Bennekou 2001) and the electroneutral potassium chlo-
ride (K-Cl) co-transport (Brugnara 1986; Su 1999). A role for the
energy driven Na-K pump system has also been identified as con-
tributing to sickled red cell abnormalities (Joiner 1993). Specific
inhibitors for either the Gardos channel or the conductive Cl−
pathway have been developed for SCD, but no specific pharmaco-
logical blockers are available for the K-Cl co-transport (Brugnara
1993b; De Franceschi 1995; De Franceschi 1996), whose activity
is regulated by magnesium (Mg) concentration and through a bal-
ance between kinase(s) and phosphatase(s) (De Franceschi 1997).
Description of the intervention
Studies in recent decades have highlighted the high bio-complex-
ity of SCD, which requires the development of new therapeutic
strategies. These strategies should be oriented towards multiple
7Magnesium for treating sickle cell disease (Review)
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targets in order to affect the range of clinical manifestations of
SCD.
Magnesium is needed for more than 300 biochemical reactions
in the body to maintain various cellular functions in different or-
gans. A normal adult human body contains approximately 1000
mmol of Mg (22 g to 26 g), most of which is present in bone
(up to 60%) and the remainder is present in skeletal muscle, soft
tissues, extracellular fluid and intracellular fluid. Total serum Mg
ranges from 0.70 to 1.10 mmol/L (Saris 2000). Generally, Mg
is absorbed in the small intestine and excreted through kidneys
(Rude 1998). The mean (standard deviation (SD)) daily dietary
intake of Mg in a UK study was reported as 418 (120) mg for men
and 343 (94) mg for women (Britton 1994). The recommended
daily allowance (RDA) in adults is 4.5 mg/kg/day. The require-
ment is higher in pregnancy or during lactation and debilitating
illness (Saris 2000). Supplementation with Mg may be indicated
in a number of specific health conditions such as cardiovascular
diseases, neurological disorders, bronchospasm, spinal cord injury
or diabetes which are characterized by Mg cellular deficiency or a
relative reduction in Mg absorption (Ladefoged 1996; Vormann
2003; Wester 1987).
Magnesiumplays a key role in heart rhythm, immune system func-
tions, bone metabolism, sugar metabolism and arterial blood pres-
sure (Patel 2014; Galli-Tsinopoulou 2014; Orchard 2014; Saris
2000;Wester 1987). IntracellularMg is an important co-factor for
various enzymes, transporters, and nucleic acids that are essential
for replication and energy metabolism (Bringhurst 2012). Magne-
sium also plays a crucial role in the modulation of endothelial in-
flammation, which may be beneficial in SCD, a pro-inflammatory
disease with increased circulating levels of inflammatory cytokines
IL-1b, IL-6 and TNFa, and expression of endothelial VCAM-1
(Brittain 2007; Maier 2004; Makis 2000). This modulation may
be beneficial with increased circulating levels of cytokines in a pro-
inflammatory SCD disease with painful crisis.
Intravenous Mg reduces VOCs through two mechanisms: a di-
rect inhibition of calcium in the vascular smooth-muscle wall; and
an endothelial-dependent release of nitric oxide (Mathew 1988;
Yang 2000). Moderate adverse effects of intravenous Mg sulphate
administration are vomiting, nausea, a feeling of warmth, flush-
ing, hypotension, bradycardia, somnolence, double vision, slurred
speech and weakness, in particular when it is rapidly administered.
These side effects usually occur when the total plasma magnesium
level reaches 3.5 to 5 mmol/L (almost double the normal Mg
plasma levels) (Knochel 1997; Hermans 1996). The most severe
effects of severe hypermagnesaemia (defined as Mg levels of 5 to
10mmol/L) are neurological (e.g. fixed and dilated pupils, muscu-
lar paralysis, hyporeflexia, neuromuscular block with respiratory
failure) (Rizzo 1993) and cardiovascular (e.g. junctional or sinus
bradycardia, sinoatrial block, atrioventricular block, and asystole)
(Berns 1976; Knochel 1997; Mauskop 1998).
Oral Mg is an important regulator of different ion transport and
membrane systems, either directly in exchange systems such as the
Na-Mg exchange or the K-Cl co-transport (De Franceschi 2001;
De Franceschi 2006; Rivera 2005); or indirectly as an essential
co-factor for sodium-stimulated phosphorylation of the sodium
potassium adenosine triphosphate metabolism (ATP) (Na-K AT-
Pase) (Flatman 1981). Oral Mg supplementation with different
preparations such as Mg sulphate, Mg glutamate or Mg pidolate
can cause some mild side effects such as diarrhoea and abdominal
cramps (De Franceschi 1997).
How the intervention might work
Red blood cell dehydration in SCD is related to cyclic HbS poly-
merisation which is associated with reduced red cell Mg content.
The reduced red cell Mg content is most likely related to abnor-
mal red cell membrane permeability to double-charged ions such
as Mg and calcium (Ca) during deoxygenation events and to the
abnormal activation of theNa-Mg exchange (De Franceschi 1997;
De Franceschi 2000; Rivera 2005). The role of Mg content in ery-
throcytes for regulating K-Cl co-transport has been demonstrated
in normal human controls and people with SCD (Brugnara 1987;
Canessa 1987). Studies on the level of Mg content are variable;
some studies showed normal circulating levels of Mg (Akenami
1999; Oladipo 2005), while others reported low levels (Olukoga
1990; Zehtabchi 2004). However, plasma levels do not reflect the
intracellular Mg content and the amount of free Mg, which is im-
portant in the context of cellular functions (De Franceschi 2001;
De Franceschi 2006).
In SCD, red cell dehydration is related to abnormally high red
cell membrane permeability during deoxygenation and the loss of
potassium through the activation of two important pathways: the
Gardos channel (Vandorpe 1998); and the K-Cl co-transporter
(Brugnara 1986; Brugnara 1995). The activity of the K-Cl co-
transport is affected by cell Mg content, oxidative stress and cyclic
phosphorylation and dephosphorylation events (Brugnara 1993b;
De Franceschi 1995; De Franceschi 1997; De Franceschi 2000);
increased red cellMg levels can inhibit the K-Cl cotransport activ-
ity (Brugnara 1993b; De Franceschi 1995; De Franceschi 1997;
De Franceschi 2000). Thus, changes in red cell Mg content in
SCD can reduce the abnormal activation of K-Cl co-transport,
preventing at least one of the components of sickle red cell dehy-
dration (Brugnara 1987; Brugnara 1995).
Several uncontrolled studies have reported beneficial effects of the
intravenous administration of Mg sulphate or the oral administra-
tion of Mg citrate in people with SCD (Anstall 1959; Lehmann
1963).
In one study, intravenous Mg sulphate was administered in chil-
dren with SS type of SCD being treated for painful crises; it was
observed that the length of hospital stay decreased (Brousseau
2004). As there were no previous studies of Mg supplementation
in children in with SCD, the dosage of intravenous Mg sulphate
was lower than the dose used for other conditions (40 mg/kg)
(Buchanan 2004). In another study, intravenous Mg sulphate was
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administered in people with SS or HbS β-thalassaemia experi-
encing sickle cell pain crisis. It was seen that treatment decreased
the duration of the VOC and subsequently decreased in length of
hospital stay (Badaki 2014).
It has been observed that oral Mg supplements, such as Mg pi-
dolate, have significantly improved red cell hydration by reduc-
ing the number of dense sickle erythrocytes, absolute reticulo-
cyte count and immature reticulocytes, while erythrocyte Mg and
potassium content were significantly increased (De Franceschi
1997; De Franceschi 2000; Zehtabchi 2004). One study used oral
Mg as a short-term treatment (less than four weeks) at a dose of 0.6
morphine equivalent (meq)/kg/day (504 mg/day) (De Franceschi
1997) and another unblinded trial study usedMg pidolate in peo-
ple with SCD homozygous for HbS (SS) as a long-term treatment
at a dose of 540 mg/day for six months (De Franceschi 2000). The
later study found that there was significantly reduced number of
painful days during the six-month period.
Why it is important to do this review
This review aims to bring together evidence for the impact of
intravenous Mg to reduce the pain and improve the quality of
life in people with different SCD genotypes who are admitted to
hospital for a painful crisis. It also aims to find out the effects of
longer-term oral Mg on the frequency of painful crises and on the
quality of life of people who are in a steady state of SCD, in order
to ameliorate red cell dehydration and hematological phenotype.
This reviewhopes to establish the clinical value of a pharmaceutical
approach.
O B J E C T I V E S
To evaluate the effects of intravenous Mg on the length of hospital
stay and quality of life in children and adults with SCD.
To determine the effects of oral Mg therapy on the frequency of
painful crises and the quality of life in children and adults with
SCD.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled studies and quasi-randomized controlled
studies (controlled clinical studies).
Types of participants
Children and adults with SCD regardless of genotype such as sickle
cell anaemia (HbSS), haemoglobin SCdisease (HbSC) and S beta-
thalassaemia (Sβ+ and Sβ 0) and of both sexes were eligible for
inclusion.
Types of interventions
Intravenous administration of Mg to children and adults (of any
genotype) at any dose and any duration at hospital admission for
acute pain crisis compared to either placeboor no supplementation
(we regarded short term as less than four weeks).
Oral administration ofMg to children and adults (of any genotype)
at any dose and any duration (we regarded short term as less than
four weeks and long term as from six months and less than two
years) with at least one painful crisis in previous one year compared
to either placebo or no supplementation.
Types of outcome measures
Primary outcomes
1. Change in frequency of vaso-occlusive painful crises as
measured by
i) pain diary of days with significant pain
ii) number of painful days (where the pain is strong
enough to require analgesics)
2. Quality of life (measured using a validated scale)
3. Length of hospital stay
Secondary outcomes
1. Change in dense red cells in SCD
i) change in mean corpuscular haemoglobin
concentration (MCHC)
ii) change in red cell distribution width (RDW)
iii) change in percentage of dense red cells (determined by
phthalate density method)
2. Amelioration of hematological phenotype
i) haematological parameters (complete blood count
(full blood count) including erythrocyte indices, reticulocyte
percentage)
ii) biochemical parameters (blood urea nitrogen (BUN),
creatinine, alanine amino transferase (ALT), aspartate amino
transferase (AST) and blood chemistries using standard assays on
a chemistry analyser)
3. Effects on K-Cl co-transport, red cell K+ and Mg2+
content (as determined with atomic absorption spectrometry
(De Franceschi 1999))
i) erythrocytes
ii) potassium
iii) sodium
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4. Adverse effects
i) mild, e.g. abdominal cramps, unpleasant flushing,
nausea, vomiting, diarrhoea
ii) moderate, e.g. vomiting , nausea, feeling warmth,
flushing, hypotension, bradycardia
iii) severe, e.g. cardiac arrhythmias, somnolence, double
vision, slurred speech and weakness
Search methods for identification of studies
We searched for all relevant published and unpublished studies
without restrictions on language, year or publication status.
Electronic searches
We identified relevant studies from the Cystic Fibrosis & Genetic
Disorders Group’s Haemoglobinopathies Trials Register using the
terms: (sickle cell OR (haemoglobinopathies ANDgeneral)) AND
magnesium.
The Haemoglobinopathies Trials Register is compiled from elec-
tronic searches of theCochraneCentral Register of ControlledTri-
als (CENTRAL) (updated each new issue of theCochrane Library)
and weekly searches of MEDLINE. Unpublished work is iden-
tified by searching the abstract books of five major conferences:
the EuropeanHaematology Association conference; the American
Society of Hematology conference; the British Society for Haema-
tology Annual Scientific Meeting; the Caribbean Health Research
Council Meetings; and the National Sickle Cell Disease Program
Annual Meeting. For full details of all searching activities for the
register, please see the relevant section of the Cochrane Cystic Fi-
brosis and Genetic Disorders Group website.
Date of last search: 01 December 2016.
Using the search terms supplied in the appendices, we searched
the clinical trial registries clinicaltrials.gov (clinicaltrials.gov/),
WHO International Clinical Trials Registry Platform (WHO
ICTRP) (http://www.who.int/ictrp/en/) and metaRegister of
Current Controlled Trials (mRCT) (www.controlled-trials.com/
mrct/) (Appendix 1).
Date of last search: 29 March 2017.
We searched the PubMed database (www.ncbi.nlm.nih.gov/
pubmed) for potentially relevant trials from 1946 to date (
Appendix 1).
Date of last search: 01 April 2017.
Searching other resources
We also checked the references of the retrieved relevant articles to
identify any additional studies. We made personal contact with
experts and researchers in the field to ask for additional studies
including unpublished and ongoing studies.
Data collection and analysis
Selection of studies
Two authors (NNT and HHKS) independently examined the ti-
tles and abstracts of the articles from electronic searches to remove
any obviously irrelevant reports. The same two authors indepen-
dently retrieved and reviewed full texts of the remaining articles
to allow us to decide whether to include or exclude these accord-
ing to the review’s inclusion criteria. We were not blinded about
the information of articles such as the journal of publication, the
names of authors, the institution or the study results. We linked
the multiple reports of the same study together. There was no dis-
agreement about the inclusion of a study. However, if there are any
disagreements in future, the two review authors will resolve the
issue by discussion or by consulting a third review author (ALA).
The review authors corresponded with other investigators, when
required, to obtain further details of the study and missing infor-
mation to clarify study eligibility and to allow a decision on the
selection of studies. We listed the excluded studies with the reasons
for exclusion in the Characteristics of excluded studies table.
Data extraction and management
Two authors (NNT andHHKS) independently extracted the data
from the studies which fulfilled the inclusion criteria using a stan-
dard data collection form and checked these for consistency. There
were no disagreements; however, if there are any disagreements
in future, we will resolve these by discussion. If required, we will
consult with a third review author (ALA) to reach a consensus.
We corresponded with original author(s) if the information in the
published article was missing or not clear. One author (HHKS)
entered data into the RevMan software (RevMan 2014), and a
second author (ALA) checked for any errors.
We extracted the following information as far as possible:
• source (study ID (created by review author), report ID
(created by review author), review author ID (created by review
author), citation (journal or conference, year of publication,
etc.), contact details);
• eligibility (confirmed eligibility for review or reason for
exclusion);
• methods (study design, study setting, time and duration of
study, sequence generation, allocation sequence concealment,
blinding, other concerns about bias);
• participants (total number, eligibility criteria (inclusion and
exclusion criteria), age and sex of participants);
• interventions (total number of intervention groups for each
intervention and comparison group of interest: dose of
intervention; routes of delivery; timing of administration;
frequency of administration; duration of intervention; co-
interventions (if any));
• outcomes (for each outcome of interest: outcome definition
(diagnostic method, name of scale, definition of threshold); units
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of measurement (if relevant); for scales, upper and lower limits,
and whether a high or low score is favourable);
• results (number of participants allocated to each
intervention group, for each outcome of interest: sample size;
missing participants; summary data for each intervention group
(mean and standard deviation (SD) for continuous data, 2 x 2
table for dichotomous data, etc);
• miscellaneous (key conclusions of the study authors,
references to other relevant studies; funding source;
correspondence required).
We extracted data frommultiple reports of the same study directly
into a single data collection form. We planned to group the out-
come data into those measured at one month, up to three months,
up to six months, up to one year and over one year. The data we
are currently able to present are from the ’up to one month’ period
(Brousseau 2015; Goldman 2013). For any studies included in
future updates of the review, we will also record any outcome data
which measured at other time periods (Higgins 2011a).
Assessment of risk of bias in included studies
Two authors (NNT and HHKS) independently assessed the risk
of bias of included studies in seven domains as listed below. In
each domain, we assigned a judgment of ’low risk’, ’high risk’
or ’unclear risk’ of bias according to the criteria described in the
Cochrane Handbook of Systematic Reviews of Interventions (Higgins
2011b).
• Sequence generation: low risk of bias (if the investigators
included random component in sequence generation process
such as using random number table, computer-generated
random number, coin tossing, shuffling cards or envelopes, etc.);
high risk of bias (if the investigators included a non-random
component in sequence generation process such as the use of
date of birth, date of admission, hospital or clinic record
number, etc.); or unclear risk of bias (If there is no sufficient
information about sequence generation process to judge whether
high or low risk).
• Allocation concealment: low risk of bias (If the investigators
used the methods such as central allocation, sequentially
numbered drug containers of identical appearance, sequentially
numbered opaque or sealed envelopes so that participants and
investigator enrolling could not foresee the assignment); high
risk of bias (If the investigators used an open random allocation
schedule, non-opaque envelops and any other quasi-randomized
methods such as alternation or rotation, case record number, etc.
so that participants and investigator enrolling could possibly
foresee the assignment); or unclear risk of bias (if method of
concealment is not described or there is no sufficient
information to judge whether high or low risk).
• Blinding of participants and personnel: low risk of bias (if
blinding was done to the study participants or personnel and the
method of blinding is described); high risk of bias (if no blinding
or incomplete blinding was done to study participants and
personnel); or unclear risk of bias (if there is no sufficient
information to judge whether high or low risk).
• Blinding of outcome assessment: low risk of bias (if
blinding was done to outcome assessors and method of blinding
was described); high risk of bias (if blinding was not done to
outcome assessors or if blinding was done, but likely it was
broken); or unclear risk of bias (if there is no sufficient
information to judge whether high or low risk).
• Incomplete outcome data: low risk of bias (no attrition, the
number of dropouts or withdrawals was balanced in intervention
groups with similar reasons); high risk of bias (imbalance of
dropouts or withdrawals in intervention groups, the number and
reasons of dropouts or withdrawals was not described); or
unclear risk of bias: If there is no sufficient information of
attrition or exclusions to judge whether high or low risk.
• Selective outcome reporting: low risk of bias (all the study’s
pre-specified outcomes of interest were reported); high risk of
bias (not all the study’s pre-specified outcomes of interest were
reported, use of not pre-specified measurement for assessing
outcomes, incomplete reporting of outcome data); or unclear
risk of bias (if there is no sufficient information to judge whether
high or low risk).
• Other sources of bias: low risk of bias (the study appears to
be free of other source of bias); high risk of bias (presence of
other source of bias); or unclear risk of bias (if there is no
sufficient information to judge whether high or low risk).
The two review authors were not blinded to the names of study
authors, institutions, journals and results of included studies. We
discussed any discrepancies when assessing the risks of bias for a
study. If we were not able to reach a consensus, we consulted a
third review author (ALA). We contacted principal investigators
to provide additional information which we thought was missing
or unclear to allow us to make a risk of bias judgement.
Measures of treatment effect
We reported dichotomous data (adverse events) using the risk ratio
(RR) with 95% confidence intervals (CIs). We reported continu-
ous data (pain scores, QoL and length of hospital stay) using the
mean difference (MD) with 95% CIs for outcomes measured us-
ing the same scale between studies. If different studies had used dif-
ferent scales for measuring the same outcome, the review authors
would have reported the standardized mean difference (SMD).
Unit of analysis issues
If the authors had included cluster-randomized studies and if there
had been little heterogeneity between all included studies, we
would have pooled the results from both individually randomized
studies and cluster-randomized studies.
For cross-over studies, if we believed there was a carryover effect
or where second-period data were not available, we planned to in-
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clude only data from the first period in themeta-analysis (Elbourne
2002). We contacted principle investigator of the De Montalem-
bert cross-over study to clarify where data were presented sepa-
rately by time period, but investigators were unable to provide
information regarding the time point (De Montalembert 2003).
As we were not able to clarify whether these data are from the first
or second period of time we have presented the results narratively
and in the additional tables.
In future updates of the review, if we include studies where there is
no carry-over effect and second period data are available, we will
collect the mean difference of measurements on the experimen-
tal intervention (E) and on the control intervention (C) of each
participant and its standard error (SE). We will include the effect
estimate and its SE in the meta-analysis using the generic inverse
variance method in Review Manager (RevMan 2014).
If, in future updates of the review, we identify and include studies
with more than two intervention groups, we will determine the
relevant groups and, if necessary, combine the relevant groups to
create a single pair-wise comparison.
Dealing with missing data
Some of the studies we included have only been published in ab-
stract form or presented at meetings or conferences. We therefore
corresponded with the investigators to request full reports; we are
still awaiting responses to allow us to draw our conclusions. We
investigated attrition rates including dropouts, withdrawals and
loss to follow up. For the missing or unclear data, or missing data
with no reported reason for dropout, we contacted the study in-
vestigator to provide further information, but are still awaiting
responses (Higgins 2011c).
Assessment of heterogeneity
Weassessed the clinical,methodological and statistical heterogene-
ity of the included studies. For clinical heterogeneity, we assessed
the variability in intervention, participants and outcomes studied.
For methodological heterogeneity, we assessed the sequence gen-
eration, allocation concealment, blinding, and differences in out-
come assessment. We used the Chi² test to determine statistical
heterogeneity and we assessed P value less than 0.10 as statistically
not significant. We were able to combine data from two studies
for one adverse event (hypotension) and I² was 0% (no important
heterogeneity) (Analysis 1.5) (Deeks 2011; Higgins 2003).
Assessment of reporting biases
We were able to compare four of the protocols of included studies
with the final report of methods and results sections to identify the
selective outcome reporting (Brousseau 2015; CHAMPS 2011;
Goldman 2013; Mueller 2005). We plan to use funnel plot in
future updates (if we include at least 10 studies) to access the pos-
sibility of publication bias in studies, as recommended in chapter
10 of the Cochrane Handbook of Systematic Reviews of Interventions
(Sterne 2011). If there is asymmetry, the possible causes of asym-
metry may include true heterogeneity, high risk of bias or poor
methodological quality, publication bias and selective outcome re-
porting.
Data synthesis
The authors presented the available data from two of the included
studies in a meta-analysis using the RevMan software (RevMan
2014). We used a fixed-effect model since we only combined data
in a single instance; and the level of heterogeneity was not impor-
tant. If, in future updates of the review, we are able to combine data
from multiple studies and there is less than moderate heterogene-
ity among the included studies, we will continue to analyse the
data using a fixed-effect model. However, we will use a random-
effects model if we identify at least moderate heterogeneity (where
the I² value is at 50% or more, which we regard as statistically
significant heterogeneity).
Subgroup analysis and investigation of heterogeneity
If, in future, the authors are able to include sufficient studies (at
least 10) in a meta-analysis and they identify at least 50% hetero-
geneity, we plan to undertake the following subgroup analyses:
1. types of SCD (HbSS, HbSC disease, S β-thalassaemia);
2. demographic status (age less than 18 years or more than 18
years; male versus female);
3. different doses of Mg supplementation (any dose used in
oral or parenteral administration);
4. different forms of Mg supplements (Mg pidolate, Mg
sulphate, etc).
Sensitivity analysis
If we are able to include sufficient studies (at least 10) in a meta-
analysis, we plan to perform a sensitivity analysis where we exclude
the studies judged to have a high risk of bias (e.g. high or un-
clear risk of bias in allocation concealment, blinding, incomplete
outcome data). We will perform the meta-analysis twice; firstly,
including all studies and then including only studies that do not
have a high risk of bias. We will also perform the meta-analysis
twice using firstly a fixed-effect model and then a random-effects
model to assess how robust the findings are to the choice of analysis
method. Finally, we will also perform sensitivity analysis to inves-
tigate the robustness of our conclusions when combining cluster-
randomized studies with individually randomized studies. We will
report any sensitivity analyses of data by producing a summary
table.
Summary of findings tables
In a post hoc change, we produced summary of findings tables
usingGRADEProfiler (GRADEpro 2014).We included one table
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for the comparison of intravenous Mg sulphate versus placebo
(Summary of findings for the main comparison) and one table for
the comparison of oral Mg versus placebo (Summary of findings
2). For the intravenous Mg table, we presented the outcomes:
change in frequency of painful VOCs (measured by pain diary
day of significant pain); length of hospital stay; Child self-reported
QoL; hypotension; and warm at infusion site for intravenous Mg
(Summary of findings for the main comparison). For the oral Mg
table we presented the outcomes: change in frequency of painful
VOCs (measured by number of painful days); QoL; length of
hospital stay; change in dense red cells; biochemical parameters;
and adverse events (Summary of findings 2).
R E S U L T S
Description of studies
See Characteristics of included studies and Characteristics of
excluded studies.
Results of the search
We identified 10 studies with 22 references in our searches, five
studies (16 references) were included (Brousseau 2015; CHAMPS
2011; De Montalembert 2003; Goldman 2013; Mueller 2005).
Four studies were excluded each with one full-text article (
Brousseau 2004; De Franceschi 1997; De Franceschi 2000;
Hankins 2007). One study (with two abstracts) is listed as ’Await-
ing classification’ and will be either included or excluded when
we have further information (Voskaridou 2000). This process is
detailed in the PRISMA diagram (Figure 1).
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Figure 1. Study flow diagram.
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Included studies
There are three included studies for oral Mg treatment (CHAMPS
2011; De Montalembert 2003; Mueller 2005) and two in-
cluded studies for intravenous Mg in treating people with SCD
(Brousseau 2015; Goldman 2013). The number of participants
in the studies of oral Mg ranged from 12 children (Mueller 2005)
to 24 children (De Montalembert 2003); and in the studies of
intravenous IV Mg ranged from 104 children (Goldman 2013) to
202 participants (Brousseau 2015).
Trial design
All five included studies were randomized; three were of parallel
design (Brousseau 2015; CHAMPS 2011’ Goldman 2013) and
two were of cross-over design (De Montalembert 2003; Mueller
2005). Four of the studies had two treatment arms (Brousseau
2015; De Montalembert 2003; Goldman 2013; Mueller 2005),
but one compared four separate treatment groups (factorial design)
(CHAMPS 2011). Two studies were short-term studies of people
admitted to the emergency department for a VOC (Brousseau
2015; Goldman 2013), but the remaining three studies were of
longer duration (at least six months of treatment) and outpatient-
based (CHAMPS 2011; De Montalembert 2003; Mueller 2005).
One study was conducted in Europe (De Montalembert 2003),
one in Canada (Goldman 2013) and three in the USA (Brousseau
2015; CHAMPS 2011; Mueller 2005).
Participants
The numbers of participants in the two intravenous Mg studies
(202 (Brousseau 2015) and 104 (Goldman 2013)) were greater
than in the oral Mg studies (which ranged from 12 (Mueller
2005) to 24 children (De Montalembert 2003)). Three studies
included only paediatric participants (i.e. up to 18 years of age)
(DeMontalembert 2003; Goldman 2013;Mueller 2005) and two
studies included both adults and children; one with an age range
of five to 53 years, although 73% of participants were under the
age of 16 (CHAMPS 2011) and the final study recruited partici-
pants aged between four and 21 years; 60% were in the stratified
age group of 12 to 21 years old (Brousseau 2015). All five stud-
ies reported on the gender split of participants and in all studies
there were more males than females. In four of the studies the
split was almost equal (CHAMPS 2011; Goldman 2013; Mueller
2005), but in one study there were significantly more males (71%)
than females (De Montalembert 2003). For the three long-term
studies, all participants had experienced at least one VOC in the
previous 12 months (CHAMPS 2011; De Montalembert 2003;
Mueller 2005). One study described participants as having SCD
(De Montalembert 2003); two studies specified participants had
HbSC (CHAMPS 2011;Mueller 2005); the fourth study included
a range of participants: 61 (58.6%) had homozygous sickle cell
anaemia; 33 (31.7%) had sickle haemoglobin C disease; and 10
(9.6%) had sickle beta thalassaemia (Goldman 2013) and the fifth
study reported that 92 participants (91%) in the Mg group had
HgbSS and 98 participants (95%) in the control group had Hg-
bSS (Brousseau 2015).
There is a discrepancy in the stated number of participants in
Goldman study between the two publications relating to this
study (MAST study- NCT00313963); the 2011 paper states that
107 participants were randomized and 104 included in the study,
but the 2013 paper states that 106 participants were included
(Goldman 2013). There is also a discrepancy in the number of
participants described in the MAGiC study (Brousseau 2015).
The primary paper states that 202 participants were enrolled
(Brousseau 2015); however a paper by Brandow reporting sec-
ondary data analysis of this study looking at opoid used (in emer-
gency department and during hospital admission) reported 204
participants were enrolled. We have contacted the authors of both
studies for further clarification.
Interventions
Study Treatment Control Trial design
Brousseau 2015 Intravenous Mg sulphate
Dosage: 40 mg/kg (max 2.4 g)
. Infused at a concentration of
40 mg/mL, 8-hourly, total of 6
doses
Placebo (normal saline) Randomized parallel study
Goldman 2013 Intravenous Mg sulphate
Dosage: 8-hourly doses of 100
mg/kg, maximum of 2 g per
dose
Placebo (saline) Randomized parallel study
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(Continued)
CHAMPS 2011 Oral Mg pidolate
Liquid
Dosage: 0.3 mmol/kg/day in
twice daily doses
Placebo or hydroxyurea
(data from comparison of Mg
versus hydroxyurea not eligible
for inclusion in this review)
Randomized parallel study (fac-
torial design)
De Montalembert 2003 Oral Mg pidolate
Blisters containing 1500 mg of
pyrolidone carboxylate of Mg
Dosage: 1, 2, 3 or 4 blisters per
day depending on weight
Placebo Randomized cross-over study
Mueller 2005
(NCT 00040456)
Oral Mg pidolate
Liquid
Dosage: 0.6 meq Mg pidolate/
kg body weight per day divided
into 2 daily doses
Placebo Randomized cross-over study
All five studies compared the active intervention to a placebo con-
trol group (Brousseau 2015; CHAMPS 2011; De Montalembert
2003;Goldman2013;Mueller 2005); one study additionally com-
pared oral Mg pidolate to oral hydroxyurea (these data are not
presented in this review as we are only comparing Mg to placebo
or no treatment) (CHAMPS 2011).
Two studies treating participants for a painful crisis compared
intravenous Mg sulphate to saline (Brousseau 2015; Goldman
2013). The doses were both given every eight hours, but differed
in volume; one study administered 40 mg/kg to a maximum of
2.4 g with a maximum total of six doses until discharge (Brousseau
2015) and the second administered 100 mg/kg to a maximum of
2 g per dose (Goldman 2013).
Three studies used oral Mg pidolate as the active intervention
(CHAMPS 2011; De Montalembert 2003; Mueller 2005). One
study used once-daily blisters whose tablets containing 1500mg of
pyrolidone carboxylate ofMg; the number of tablets (and therefore
the amount of treatment drug) depended on the weight of the par-
ticipant (De Montalembert 2003). Two studies gave twice-daily
doses of Mg pidolate in liquid form (CHAMPS 2011; Mueller
2005). The doses were 0.6 meq Mg pidolate/kg body weight per
day (Mueller 2005) and 0.3 mmol/kg/day (CHAMPS 2011).
Outcomes
Three of the studies reported on the review’s primary outcome of
pain (De Montalembert 2003; Goldman 2013; Mueller 2005);
but the study of intravenous Mg sulphate for the relief of a VOC
had a slightly different focus than the longer-term studies and
only looked at the mean daily pain intensity and cumulative anal-
gesic requirement (Brousseau 2015; Goldman 2013). Two stud-
ies reported on the number of painful days (De Montalembert
2003; Mueller 2005), one of these studies additionally reported
on pain intensity and the amount of analgesic administered (De
Montalembert 2003). One study reported on the review’s second
primary outcome HRQoL (Brousseau 2015); length of hospital
stay (third primary outcome) was reported by two the short-term
studies (Brousseau 2015; Goldman 2013). The secondary out-
come measures of changes in dense red cell and amelioration of
hematological phenotype outcome measures were not reported by
any of the included studies (De Montalembert 2003; Goldman
2013; Mueller 2005; CHAMPS 2011). Effects of Mg2+ content
was reported by one study (De Montalembert 2003). Three stud-
ies reported adverse events but not split according to severity as we
had planned to report (Brousseau 2015; Goldman 2013; Mueller
2005).
Excluded studies
We excluded four studies since none of them were random-
ized (Brousseau 2004; De Franceschi 1997; De Franceschi 2000;
Hankins 2007) (see Characteristics of excluded studies).
Studies awaiting classification
There is only one controlled clinical study which is listed as await-
ing classification (Voskaridou 2000). The study was published as
an abstract only which does not allow us to adequately assess the
design against our inclusion criteria. The study included 10 adults
who were diagnosed with βS /β thalassaemia disease. Five adults
received 0.6 mE/kg/day of oral of Mg aspartate for six months (af-
ter informed consent) and a further five adults received a placebo
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for six months. The outcomes measured were an arbitrary scoring
of clinical severity; follow up of main red cell parameters along
with the level of intracellular and serumMg and the density of red
cell distribution.
Risk of bias in included studies
Overall, we judged the included studies to have a moderate risk of
bias (Figure 2; Figure 3).
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Sequence generation
Two of the included studies were judged to have an unclear risk of
bias for sequence generation as neither study described themethod
of randomization (De Montalembert 2003; Mueller 2005). The
De Montalembert study states that participants were randomly
allocated to one of the two arms - either six months ofMg pidolate
followed by a three-month washout period and then six months
of placebo or the reverse order (De Montalembert 2003). The
Mueller study states that participants were randomized to either
receive oral Mg pidolate or placebo for six months followed by a
washout period and six months of the other agent with a further
washout period (Mueller 2005).
We judged three studies to have a low risk of bias for sequence
generation (Brousseau 2015; CHAMPS 2011; Goldman 2013).
In Brousseau study, randomization tables were provided by the
data co-ordinating centre and used randomly varying block sizes
for equal allocation stratified by age group, study site and hy-
droxyurea use during past three months (Brousseau 2015). In the
Goldman study, participants were also randomly assigned to treat-
ment group by the research pharmacy using preset randomization
tables (blocks of four) (Goldman 2013). In the CHAMPS study
the allocation sequence was generated using a sequential allocation
algorithm (CHAMPS 2011).
Allocation concealment
The two studies which had an unclear risk of bias for sequence
generation also had an unclear risk of bias for allocation conceal-
ment, again due to a lack of clear information (CHAMPS 2011;
Mueller 2005).The two studies with a low risk of bias for sequence
generation, were also graded as having a low risk of bias for alloca-
tion concealment (Brousseau 2015;Goldman 2013). InBrousseau
study, a central randomization service was used where the ran-
domization tables were provided by PECARN data co-ordinating
centres to the research pharmacy preparing the drugs at each study
site (Brousseau 2015). In the Goldman study, the sequence was
generated by the research pharmacy (Goldman 2013). Following
contact with the deMontalembert study authors, it was confirmed
that treatments were allocated by a central randomization service,
therefore we graded this study as having a low risk of bias also (De
Montalembert 2003).
Blinding
TheDeMontalembert study was described as being double-blind,
but there was no description of the placebo or any further in-
formation in the abstract to allow us to make a clear judgement;
therefore, we contacted the lead author who confirmed that there
was a full blinding of participants and personnel as treatment and
placebo were not distinguishable and we have graded this study
as having an low risk of bias for blinding of participants, person-
nel and outcome assessors (De Montalembert 2003). We graded
the remaining four studies as having a low risk of bias for partici-
pants and personnel as they are all described as being double-blind
and give descriptions of placebo treatments that were indistin-
guishable from the study medication (Brousseau 2015; Goldman
2013; Mueller 2005; CHAMPS 2011). However, we graded these
four studies as having an unclear risk of bias for blinding of out-
come assessors since, although they were described as being dou-
ble blind and in some cases it was stated (e.g. on a trial registry)
that blinding included outcome assessors, no further details were
given (Brousseau 2015;Goldman 2013;Mueller 2005; CHAMPS
2011).
Incomplete outcome data
Wegraded one included study as having a high risk of attrition bias
(CHAMPS 2011). The CHAMPS study enrolled 64 participants
and 44 of these were randomized; 36 participants completed eight
weeks of the study but only 22 participants completed the full 44
weeks providing data for the primary end point (CHAMPS 2011).
We graded one included study as having an low risk of attrition bias
(De Montalembert 2003). The number of participants in the De
Montalembert study was stated in the abstract as 24 with no men-
tion of the number randomized or if there were any withdrawals,
but the lead author later confirmed that 24 participants were ran-
domized and there were nowithdrawals (DeMontalembert 2003).
However, we judged the remaining three studies as having low
risk of attrition bias (Brousseau 2015; Goldman 2013; Mueller
2005). InBrousseau study, 208 childrenwere randomized and 204
children received study drug (Brousseau 2015). In the Goldman
study, 106 children were randomly assigned to treatment arms in
the study, 104 participants were included (two withdrew consent)
and 98 provided data (Goldman 2013). In theMueller study, only
five out of 12 participants were evaluated for efficacy; however,
reasons were given for the seven participants who dropped out:
three for non-compliance, two for study violation (pharmacy dis-
pensed wrong formulation) and two withdrew citing personal rea-
sons (Mueller 2005).
Selective reporting
The study protocol for the De Montalembert study was not avail-
able, we therefore judged this study to have an unclear risk of bias
for selective outcome reporting (De Montalembert 2003).
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The remaining four included studies had protocols available from
the online trial registry clinicaltrials.gov showing a history of
changes:
• Brousseau 2015 (NCT01197417 - since 31 August 2010);
• CHAMPS 2011 (NCT00532883 - since 20 September
2007);
• Goldman 2013 (NCT00313963 - since 10 April 2006);
and
• Mueller 2005 (NCT00040456 - since 26 June 2002).
To date, the Mueller study has only been presented as a poster
with no full paper publication (Mueller 2005).We have contacted
the primary investigator of the study for information to allow us
to assess reporting bias, but we are still waiting for the reply. In
the study protocol, the stated primary outcome was to evaluate
whether treatment with oral Mg pidolate decreases the number
of painful crises; secondary outcomes were tolerance of long-term
treatment with oral Mg pidolate and the effects of Mg pidolate
therapy on K-Cl co-transport activity, red blood cell (RBC) hydra-
tion status and the intracellular Mg content of erythrocytes. Only
limited adverse event data were reported in the poster presentation
of this study, but efficacy data were due at a later date (Mueller
2005). We judged this study to have an unclear risk of bias due to
insufficient information to allow a judgement.
Three of the studies had corresponding full paper publications and
we judged them to have a low risk of bias as they reported their pre-
specified outcome measures (Brousseau 2015; CHAMPS 2011;
Goldman 2013).
The primary outcome of the Brousseau study was length of hospi-
tal stay (hours); the secondary outcomes were morphine use dur-
ing hospitalizations, adverse events (during infusion and develop-
ment of acute chest syndrome) and health-relatedQoL (both dur-
ing and after study drug infusion) (Brousseau 2015). The primary
outcome of the Goldman study was also length of hospital stay;
the secondary outcomes were a reduction of mean daily pain score
during an admission for a sickle cell pain crisis, adverse events
during admission and the cumulative volume of a narcotic drug
required to manage the crises during admission (Goldman 2013).
The primary outcome of the CHAMPS study was the proportion
of hyperdense red blood cells (red blood cells with density greater
than 41 g/dL); secondary outcomes were to document the toxicity
of both drugs (Mg and hydroxyurea) and their effects on hema-
tological parameters and red cell metabolism in people with SCD
(CHAMPS 2011).
Other potential sources of bias
We judged only one study to have a low risk of potential bias where
the author later confirmed that the authors compared the data
observed during the placebo periods (the first period for half of the
participants and the second period for the remaining participants)
and those observed during the treatment periods (the first period
for half of the participants and the second period for the remaining
participants) (De Montalembert 2003).
We judged two of the included studies to have a high risk
for other potential sources of bias (CHAMPS 2011; Goldman
2013). In the Goldman study, the targeted sample size expected
from protocol was not achieved. The estimated enrolment ranged
from 120 to 126 (see history of changes of NCT00313963 on
clinicaltrials.gov). The earlier abstract of the Goldman study pub-
lished in 2011 reported 107 individuals were randomized and 106
participated in the study. The full study publication states that a
total of 159 people were approached to participate in the study,
106 (67%) consented and two participants (2%) withdrew their
consent to participate in the study (Goldman 2013). In theWang
study, the original sample size calculation was 188 participants
across four treatment arms (see the NCT00532883 record regis-
tered on 01 September 2005 on clinicaltrials.gov), but the enrol-
ment of participants in this Phase II trial between January 2007
and August 2009 was only 44 (according to the last-updated ver-
sion of the NCT00532883 record from January 2010). The full
Wang paper states that 64 participants enrolled and 44 of these
were randomized; a total of 36 participants completed the eight
weeks of study (the primary end point evaluation), but only 22
participants completed 44 weeks of treatment. The study was ter-
minated early because of the slow enrolment (CHAMPS 2011).
The authors judged there to be an unclear risk fromother potential
sources of bias for two studies (Brousseau 2015;Mueller 2005). In
theBrousseau study, bloodMg levelswere notmeasured before and
after intravenous Mg therapy, so Mg toxicity was not monitored
(Brousseau 2015). Also the targeted sample size calculation for the
Brousseau study was 104 per arm with a total of 208 (see history
of changes on clinicaltrials.gov for NCT01197417). In the orig-
inal full publication, 410 potential participants were approached
and 208 were randomized. However, there are differences in the
number of participants described in the secondary data analysis
of the MAGiC study by Brandow, where 204 participants were
stated as being enrolled. Due to the lack of measurement of Mg
blood levels, we judged this study have an unclear for other poten-
tial sources of bias (Brousseau 2015). The Mueller study expected
to enrol 20 participants; 100 eligible potential participants were
contacted and invited to participate in the study, but according to
the current recruiting status on clinicaltrials.gov, the number of
participants recruited is 12 and the study was terminated due to
lack of accrual. A full paper has not been published and the results
for 12 participants have only been presented narratively without
data analyses (Mueller 2005).
Effects of interventions
See: Summary of findings for themain comparison Intravenous
magnesium sulphate versus placebo for treating sickle cell disease;
Summary of findings 2Oralmagnesium pidolate versus placebo/
no intervention for treating sickle cell disease
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Intravenous Mg sulphate versus control
Two studies (n = 306) compared intravenousMg sulphate to saline
for treating people admitted to hospital with a VOC (Brousseau
2015; Goldman 2013).
Primary outcomes
1. Change in frequency of vaso-occlusive painful crises
a. pain diary of days with significant pain
In the Goldman study, a total of 98 participants provided data for
104 painful episodes. The mean daily pain intensity during hos-
pitalisation was measured for the Mg sulphate and placebo groups
using the Faces Pain Scale-Revised, which has been validated for
children between four and 18 years of age (Hicks 2001). There
was no significant difference between the groups, MD 0.10 (95%
CI -0.82 to 1.02) (Analysis 1.1).
This outcome was not reported by the second included study
(Brousseau 2015).
b. number of painful days (where the pain is strong enough to
require analgesics)
The secondary data analysis ofMAGiC study byBrandow reported
the standard opoid treatment for acute pain events and LOS. The
mean total initial dose of opoid was 0.043 (0.029) mg/kg/hour
and was administered over a median of 8.5 (interquartile range
(IQR) 6.4 to 13.1) hours. The median time to first IV opoid
was 1.02 (IQR 0.65 to 1.33) hours; the median time to first oral
opioid was 28.3 (IQR 12.2 to 61.1) hours. These data and route
of administrations for opoid used were not separately mentioned
either with Mg or placebo in this paper by Brandow (Brousseau
2015).
This outcome was not reported by Goldman (Goldman 2013).
2. Quality of life (measured using a validated scale)
The Brousseau study assessed health-relatedQoL with both child-
reported and parent-reported scales - the PedsQL generic core
scales, PedsQLmulti-dimensional fatigue scales and PedsQL SCD
(Brousseau 2015). There was no significant difference in any child
self-reported scores (from ED to pre-discharge and one week fol-
low up) between the Mg and placebo groups (Analysis 1.2). Like-
wise for the parent self-reported scores from the different scales,
there were no differences shown between the Mg and the placebo
groups (Analysis 1.3). This outcome was not reported by the sec-
ond included study (Goldman 2013).
3. Length of hospital stay
Brousseau reported the median length of stay which included the
total time until discharge from the hospital regardless of the time
of last opoid (Brousseau 2015). There was no difference in length
of stay between the Mg and placebo groups. A post hoc analysis
evaluating whether Mg had an effect on the length of stay, if the
child presented early in the course of the pain crisis, also reported
nodifference in this outcome between the treatment or the placebo
groups (Table 1).
Goldman also reported the length of hospital stay counted as the
number of hours from the first study dose until the physician’s
decision to discharge the participant (Goldman 2013). This time
correlates most closely with the termination of intravenous anal-
gesia. There was no statistically significant difference between the
Mg group and the control (saline) group in length of hospital stay,
MD 14.70 hours (95% CI -20.51 to 49.91) (Analysis 1.4).
Secondary outcomes
1. Change in dense red cells
Neither included study reported any measure of the change in
dense red cells (Brousseau 2015; Goldman 2013).
2. Amelioration of hematological phenotype
Neither included study reported on this outcome (Brousseau
2015; Goldman 2013).
3. Effects on K-Cl co-transport, red cell K+ and Mg2+
content
Neither included study reported on this outcome (Brousseau
2015; Goldman 2013).
4. Adverse effects
Both studies (n = 306) reported a number of adverse events but
did not categorise them as mild, moderate or severe as we planned
to report (Brousseau 2015; Goldman 2013). We therefore present
adverse event data in summary and not by severity. When en-
tered into analysis, there was only one significant difference ad-
verse event (warmth at infusion site), but there were no significant
differences for other adverse events between the treatment and
control arms (Analysis 1.5).
Oral magnesium pidolate versus control
Three studies (n = 80) compared oral Mg pidolate to control
(CHAMPS 2011; De Montalembert 2003; Mueller 2005). The
CHAMPS paper stated a minimum and maximum number of
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participants at baseline and each visit for those receiving hydrox-
yurea with Mg or with Mg placebo which ranged from 20 to 23 at
baseline, 13 to 17 at week 8 and 12 to 13 at week 24; it also stated
the same for those participants receiving placebo hydroxyureawith
either Mg or Mg placebo which ranged from 19 to 21 at baseline,
17 to 19 at week 8 and 13 to 14 at week 24 (CHAMPS 2011).
There is no meta-analysis performed and results are summarised
narratively for outcomes comparing oral Mg and placebo group.
Primary outcomes
1. Change in frequency of vaso-occlusive painful crises
a. pain diary of days with significant pain
Only one cross-over study (n = 24) described the change in fre-
quency of VOC (number of painful days) (De Montalembert
2003). The mean (SD) (range) number of days of pain during the
six-months period in the Mg group was 8.6 (12.4) (0 to 41) days
and in the placebo group was 10.5 (12.4) (0 to 54) days. There was
no significant difference in the number of painful days between
the Mg treatment group and placebo, MD 1.90 days (95% CI -
1.05 to 4.85) (low quality evidence) (Analysis 2.1).
The remaining two studies in this comparison did not report on
this outcome (CHAMPS 2011; Mueller 2005).
b. number of painful days (where the pain is strong enough to
require analgesics)
This outcome was not reported by any of the included studies
for this comparison (CHAMPS 2011; De Montalembert 2003;
Mueller 2005).
2. Quality of life
This outcome was not reported by any of the included studies
for this comparison (CHAMPS 2011; De Montalembert 2003;
Mueller 2005).
3. Length of hospital stay
This outcome was not reported by any of the included studies
for this comparison (CHAMPS 2011; De Montalembert 2003;
Mueller 2005).
Secondary outcomes
1. Change in dense red cells in SCD
This outcome was not reported by any of the included studies
for this comparison (CHAMPS 2011; De Montalembert 2003;
Mueller 2005).
2. Amelioration of hematological phenotype
This outcome was not reported by any of the included studies
for this comparison (CHAMPS 2011; De Montalembert 2003;
Mueller 2005).
3. Effects on K-Cl co-transport, red cell K+ and Mg2+
content
Only the CHAMPS study reported on K-Cl co-transport activity
and measured chloride-dependent net K efflux (CHAMPS 2011).
No values for the SDs were available from this study for K-Cl
co-transport content effects which would have allowed us to un-
dertake a meta-analysis; we have therefore presented the available
information in the additional tables (Table 2).
a. Erythrocytes
The CHAMPS study determined the Mg content of erythrocytes
by atomic absorption spectrophotometry (CHAMPS 2011). The
meanMg levels at week eight were slightly higher in theMg group
compared with those receiving placebo (Table 2).
De Montalembert measured the RBC Mg levels every three
months (De Montalembert 2003). The mean (SD) (range) values
for RBC Mg during the six months in the Mg group were 7.19
(2.02) (4.81 to 14.8) mM/kg Hb and in the placebo group were
6.73 (1.14) (4.95 to 9.32) mM/kg Hb (P value = 0.24). When
analysed, there was no significant difference Mg in erthrocytes be-
tween the two groups, MD 0.46 mM/kg Hb (95% CI -0.29 to
1.21) (low quality evidence) (Analysis 2.2).
The third included study planned to report on “change in the
intracellular Mg content of erythrocytes” as one of the secondary
outcomes, but the available poster presentation did not present
data for this outcome (Mueller 2005).
b. potassium
In the CHAMPS study, the potassium content of erythrocytes was
determined by atomic absorption spectrophotometry (CHAMPS
2011). Again the published report did not provide values for the
SDs for K+ content effect, so we are not able to perform a meta-
analysis. Available results are presented in the additional tables
(Table 2). The two remaining included studies for this comparison
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did not report on this outcome (De Montalembert 2003; Mueller
2005).
c. sodium
In the CHAMPS study, the sodium content of erythrocytes was
determined by atomic absorption spectrophotometry (CHAMPS
2011). As before, no SDs were reported and we were not able
to undertake a meta-analysis; the available results are presented
in the additional tables (Table 2). The two remaining included
studies for this comparison did not report on this outcome (De
Montalembert 2003; Mueller 2005).
4. Adverse effects
Adverse events were not reported in the De Montalembert study
(De Montalembert 2003). In the Mueller study, which has only
been published as a scientific meeting abstract, investigators report
some narrative information on adverse events. The report states
that there were seven events probably related to the study drug
or placebo, but only one episode of diarrhoea was severe or worse
(described by the paper as grade 3 or higher). There were a fur-
ther eight events which were possibly related to the study drug or
placebo: diarrhoea in three participants (none severe or disabling
(described as grade 3 or 4)); and headache in five participants (two
were disabling (grade 4) and three were severe (grade 3)). All ad-
verse events resolved without stopping treatment (Mueller 2005).
In the CHAMPS study, a total of 38 participants reported 293
adverse events while receiving study drugs. Of these, 22 events
in 10 participants were reported as serious adverse events, but
no differences were observed across the four treatment groups in
the distribution of these events. Fifteen of the reported serious
adverse events (in nine participants) and 111 of the adverse events
(in 27 participants) were described as VOCs, but there were no
significant differences among groups. Participants also reported 42
occurrences of gastrointestinal disorders, 22 episodes of headache
or migraine, 18 upper respiratory infections and nine episodes of
rash. There were no deaths during the 26.3 participant years of
follow-up (CHAMPS 2011).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Oral magnesium versus placebo for treating sickle cell disease
Patient or population: people with sickle cell disease
Settings: outpat ient (Europe)
Intervention: oral magnesium pidolate
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo/ no interven-
tion
M agnesium
Change in frequency of
vaso-occlusive painful
crises
(as measured by pain
diary days with signifi-
cant pain)
Follow up: Not reported
NA3 The mean number of
painful days in the in-
tervent ion group was 1.
9 higher (1.05 lower to
4.85 higher) than in the
placebo group.
NA3 24
(1 study)
⊕⊕©©
low1,2
Cross-over randomized
controlled study.
There was no signif i-
cant dif f erence in the
mean number of painful
days between the inter-
vent ion group and the
placebo group
Quality of life Not reported
Length of hospital stay Not reported
Change in dense red
cells in sickle cell dis-
ease
Not reported
Effects of K-Cl co-
transport red cell K+
and M g2+ content (RBC
magnesium) mM / kg Hb
Follow up: Not reported
NA3 The mean RBC magne-
sium in the interven-
t ion group was 0.46
higher (0.29 lower to 1.
21 higher) than in the
NA3 24
(1 study)
⊕⊕⊕©
moderate2
Cross-over randomized
controlled study.
There was no signif i-
cant dif f erence in mean
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placebo group. RBC magnesium be-
tween the intervent ion
group and the placebo
group
Adverse events: diar-
rhoea and headache
Follow up: every 2
weeks then every 4
weeks.
9 events that were
considered probably re-
lated to drug (or
placebo)
12
(1 study)
⊕⊕⊕©
moderate4
Cross-over randomized
control study (Mueller
2005).
This study reported ad-
verse events as total for
both intervent ion and
placebo period
Adverse events: includ-
ing serious adverse
events, vaso-occlusive
crisis, gastrointest inal
disorder, headache or
migraine, upper respira-
tory tract infect ion, rash
Follow up: 26.3 pat ient
years of follow up
293 adverse events
while receiving study
drugs.
36 (1 study) ⊕⊕⊕©
moderate5
Phase II mult i-cen-
tre double-blinded trial,
f actorial design (
CHAMPS 2011).
This study reported ad-
verse events for four
treatment arms. No
dif ferences were ob-
served across the four
treatment groups
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; K-Cl: potassium chloride; NA: not applicable; RBC: red blood cell; RR: Risk Ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Evidence downgraded to imprecision: wide 95% CIs of the ef fects of outcomes of the intervent ion.
2Evidence downgraded due to report ing bias: the study protocol was not available.
3The results f rom the study were presented as mean dif ference so an est imate of risk within the control group is not available.
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4Evidence downgraded due to unclear risk of select ion bias (random sequence generat ion and allocat ion concealment) and
report ing bias.
5High risk of attrit ion bias: incomplete outcome data.
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D I S C U S S I O N
Summary of main results
There were five randomized controlled studies (n = 386) in-
cluded in this review (Brousseau 2015; CHAMPS 2011; De
Montalembert 2003; Goldman 2013; Mueller 2005). Two par-
allel studies examined short-term intravenous magnesium (Mg)
(Brousseau 2015; Goldman 2013) and three studies examined
longer-term oral Mg; one of these was of parallel design with four
arms comparing oral Mg pidolate to hydroxyurea and respective
placebos (only the Mg pidolate versus placebo comparison was el-
igible for inclusion in this review) (CHAMPS 2011) and two were
of cross-over design (De Montalembert 2003; Mueller 2005).
Only one (n = 104) of the two studies reporting on intravenous
Mg use reported analysable data for pain score (Goldman 2013).
There was no difference found between Mg sulphate or placebo
groups for pain score at up to one month, mean difference (MD)
0.10 (95% confidence interval (CI) -0.82 to 1.02) (Analysis 1.1).
The second study of intravenous Mg (n = 202) reported analysable
change data for health-related quality of life (HRQoL) scores be-
tween arrival at the emergency department to pre- discharge and
one week follow-up, we found there was no significant differ-
ence between Mg and placebo groups in child self-reported scores
(Analysis 1.2) or parent self-reported score (Analysis 1.3). Both
studies reported on the length of hospital stay, but data were only
analysable from one study (n = 104) (Goldman 2013) and showed
no difference between the groups, MD 14.70 hours (95% CI -
20.51 to 49.91) (Analysis 1.4). Both studies also reported a num-
ber of adverse events but did not categorise them as mild, mod-
erate or severe as we had planned to report. We therefore present
adverse event data in general and not by severity. There was sig-
nificant association of warmth at infusion site between the intra-
venous Mg sulphate group and the placebo group, but there was
no significant difference in hypotension, nausea or vomiting, pain
at the infusion site, pruritus, tachycardia, drowsiness and acute
chest syndrome (Analysis 1.5). From our analysis, there was no
clear benefit, but some harm (warmth at infusion site) identified
with intravenous Mg sulphate compared to placebo (Brousseau
2015; Goldman 2013).
One cross-over study (n = 24) comparing oral Mg pidolate to
placebo reported on one of our primary outcomes (change in fre-
quency of painful crisis) and one secondary outcome (Mg lev-
els in red blood cells); there was no significant difference re-
ported in painful days and Mg levels in RBC between the Mg
treatment group and placebo group in the six-month study (De
Montalembert 2003). The parallel CHAMPS study, (n = 44) re-
ported effects of oral Mg pidolate and placebo on potassium chlo-
ride (K-Cl) co-transport, sodium and potassium ion transport
measures but we were not able to analyse these due to insuffi-
cient information (CHAMPS 2011). We were not able to analyse
any adverse event data. One study reported no adverse events (De
Montalembert 2003) and a second study reported limited narra-
tive on adverse events all of which resolved without stopping treat-
ment (Mueller 2005). The third study reported that no differences
were observed across the four treatment groups in the distribu-
tion of adverse events such as vaso-occlusive pain crises (VOCs),
gastrointestinal disorders, headache or migraine, upper respiratory
infection or rash; there were no deaths reported (CHAMPS 2011).
Overall completeness and applicability of
evidence
Two parallel studies of intravenous Mg sulphate reported on our
all primary outcomes of pain score and length of stay in hospital in
hours and quality of life (Brousseau 2015; Goldman 2013). Only
one of the studies comparing oral Mg pidolate to placebo mea-
sured our primary outcome of change in the frequency of painful
crises as measured by pain diary days (analysable data available)
(De Montalembert 2003). None of the oral studies reported on
length of stay in hospital or quality of life (CHAMPS 2011; De
Montalembert 2003; Mueller 2005). In reporting adverse effects,
none of the studies categorised these as mild, moderate or severe
as we had originally planned to report. We therefore presented
adverse event data in general and not by the severity of the event.
We were able to analyse all the primary outcomes for the studies
of intravenous Mg sulphate, but the data were limited. We were
not able to analyse outcomes which we expected to for oral Mg
pidolate. The most common reason for this was that the interven-
tions have so far mainly been evaluated in pilot studies instead of
randomized controlled trials (RCTs); these non-randomized stud-
ies are not eligible for inclusion in our review. Furthermore, not all
the outcome measures, which we defined a priori, were assessed,
e.g. none of the included RCTs reported any change in dense red
cells and haematological effects from Mg treatment. Although we
planned to investigate whether oral Mg reduces the number of
dense erythrocytes and improves the erythrocyte membrane trans-
port abnormalities in people with sickle cell disease (SCD), we
failed to do so because complete data were not reported. In the
included studies, both oral Mg pidolate and intravenous Mg sul-
phatewere given at a lower dose than themaximally-tolerated dose,
perhaps limiting our ability to identify any biological effects on
red blood cell density. Our review provides a basis for performing
clinical efficacy studies using oral Mg or intravenous Mg sulphate
for treating SCD, whichmay improve painful episodes, reduce red
cell dehydration and length of hospital stay.
Quality of the evidence
There is a moderate level of evidence for the change in frequency
of vaso-occlusive painful crises, which demonstrated no signifi-
cant difference between intravenous Mg sulphate and the control
group in treating SCD. However, there is low quality evidence for
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the effect of intravenous Mg sulphate on length of hospital stay,
adverse events (hypotension, warm at infusion site) and HRQoL
(Summary of findings for the main comparison). With regards
to treatment with oral Mg for treating SCD, there is low quality
evidence for the assessment of painful crisis and moderate quality
evidence in the effects on K-Cl co-transport (red cell Mg content)
with oral Mg (Summary of findings 2).
Four studies were judged to be at a low risk of selection bias,
with adequate methods to generate a random sequence and to
conceal group allocation (Brousseau 2015; CHAMPS 2011; De
Montalembert 2003; Goldman 2013); the remaining study was
judged to have an unclear risk of selection bias (Mueller 2005).
Blinding of participants and personnel was only undertaken in
four studies (Brousseau 2015; CHAMPS 2011; DeMontalembert
2003; Goldman 2013), while we judged a single study to have
an unclear risk for this domain (Mueller 2005). Only one study
had a low risk of detection bias, where the outcome assessors were
blinded (Mueller 2005), the remaining studies had an unclear risk
of detection bias. Two studies were judged to have an unclear risk
of attrition bias (Goldman 2013; Mueller 2005), one study had a
high risk of attrition bias (CHAMPS 2011) and two studies had
a low risk of attrition bias (Brousseau 2015; De Montalembert
2003). Three studies were judged to be at low risk of selective
reporting bias aswewere able to confirm that they reported on each
planned outcome (Brousseau 2015; CHAMPS 2011; Goldman
2013). However, there was no available protocol for either of the
remaining studies and so it was unclear if the other two studies had
a risk of bias from this domain (De Montalembert 2003; Mueller
2005).
We assessed sample-size calculations of other potential sources of
bias and regarded one included study as having a low risk of bias
due to sample-size calculation (Brousseau 2015). In first study,
the total numbers of participants needed per arm was stated in
the protocol as being 91; however, in full article it reported that
410 people were approached to take part in the study, 208 were
randomized with 204 (98%) receiving the study drug and just
four (2%) not doing so. The number of participants included in
analysis were 100 (99%) from one arm and 102 (99%) from the
second arm. In each arm one participant (1%) withdrew with the
reason given as there being no outcome data (Brousseau 2015).
Two studies were judged to have a high risk of bias relating to
sample size calculations (CHAMPS 2011; Goldman 2013). The
historical changes in the study archive for the the Goldman study,
give the estimated enrolment ranging from 120 to 126 partici-
pants, but the full article states that a total of 159 individuals were
approached for the study, 106 (67%) consented and two partici-
pants (2%) then withdrew their consent (Goldman 2013). In the
CHAMPS study, the original sample size calculation was 188 par-
ticipants across four treatment arms, but the full article states that
64 participants were enrolled and 44 of these were randomized;
only 22 participants completed 44 weeks of the study. The study
was terminated early because of the slow enrolment (CHAMPS
2011). Finally, the two remaining studies was judged to have an
unclear risk bias due to sample sizes; one stated that the expected
sample size of 20 participants, but was terminated early due to the
lack of accrual; the full article is not yet available (Mueller 2005).
The second study has no details with regards to sample size calcu-
lations (De Montalembert 2003).
Potential biases in the review process
This review complies with the comprehensive methodology which
is applicable for finding and assessing all relevant studies. We ex-
tracted information from RCTs using standard Cochrane meth-
ods for data extraction and analysis with reference to the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011a).
We contacted the study authors to obtain further data when we
were limited by the reported data and requested protocols of their
studies to allow the inclusion and further analysis of studies. Our
review has some limitations, while we were able to access the pro-
tocols of four of the included studies and their history of changes
from a clinical trials registry; we were unable to obtain much of
the required primary data to include in our systematic analysis.
Agreements and disagreements with other
studies or reviews
There are no other reviews or studies on this topic to compare
with this Cochrane Review.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In this review, there is a lack of promising effects from either of the
included parallel RCTs using intravenous Mg to treat people with
SCD admitted to hospital for a painful crisis (where pain started
24 hours before arrival at hospital) in reducing the painful crisis
at hospital and improving HRQoL after discharge from hospital.
There is also a lack of promising evidence from any RCT, either of
parallel or cross-over design, to support the use of oral Mg to treat
people with SCD (with at least one vaso-occlusive crisis in previous
12 months) in reducing the frequency of painful crises, reducing
red cell dehydration by changing haematological and biochemi-
cal parameters and improving HRQoL. One oral Mg study was
terminated early because of slow enrolment, but narrative results
showed that no significant toxicity was observed in the Mg treat-
ment arm.
Our findings are supported by lowquality evidence for intravenous
Mg and low quality evidence for oral Mg. We are therefore unable
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to recommend that intravenous Mg sulphate or oral Mg pidolate
are used to treat children or adults who are experiencing painful
episodes or those with stable disease.
Implications for research
Neither intravenous Mg sulphate or oral Mg pidolate appear to be
effective in treating painful crises in people with SCD. However,
these conclusions are based on limited data and information from
two studies of intravenous Mg sulphate and three studies of oral
Mg pidolate, all with a small number of participants. Due to the
limited current evidence, furtherRCTs may be warranted to deter-
mine whether intravenous Mg sulphate can reduce the length of
hospital stay and improve the quality of life in people with SCD;
and whether oral Mg can improve painful episodes and reduce red
cell dehydration in people with SCD. Furthermore, data to justify
proposing oral Mg pidolate as a potential therapeutic strategy for
preventing erythrocyte dehydration in haemoglobin S disease is
needed. Such studies must be sufficiently well-designed and large
enough to allow important differences to be detected. Since no
definitive conclusions canbemade about the clinical efficacy ofMg
therapy, future research must consider further health-related out-
comes (including reporting on reducing sickle cell painful crises),
as well as improving long-term HRQoL outcomes. In addition,
studies may address specific considerations including timing and
safety of commencement of intravenous Mg sulphate and oral Mg
pidolate as well as dosage for therapeutic benefits in management
guidelines.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Brousseau 2015
Methods Randomized, parallel, double-blind placebo-controlled study set in the emergency de-
partment.
Multicentre: 8 sites (PECARN).
Location: USA.
Folllow up: by telephone 8 - 10 days post-discharge, in clinic 1 - 3months post-discharge
Participants People with HbSS or HbS thalassaemia, aged 4 - 21 years, presenting with VOC to
emergency department and being admitted for pain management were assessed for eli-
gibility
Participants randomized within 12 hours of receiving IV opioids in emergency depart-
ment
807 accessed for eligibility, 540 eligible for the study: 410 approached, 214 consented
to participate, 208 randomized and finally 202 children (100 in Mg group and 102 in
Placebo group) analysed for the outcomes
Age group 4 - 11 years (N (%)): Mg group 41 (41%), placebo group 40 (39%)
Age group 12 - 21 years (N (%)): Mg group 60 (59%), placebo group 63 (61%)
Gender (N (%)): Mg group 49 (49%) females, placebo group 56 (54%)
Interventions First dose at emergency department or inpatient floor at admission
Intervention: IV MgSO4 40 mg/kg (maximum 2.4 g) for 20 minutes every 8 hours for
a total 6 of doses or until discharge (whichever came first)
Control: IV saline placebo for 20 minutes every 8 hours for a total 6 of doses or until
discharge (whichever came first)
All participants additionally received standard therapy for VOC during hospital stay,
other SCD-specific medications administered at discretion of blinded treating physician
Outcomes Primary efficacy outcome: length of stay in hospital (from start of first medication dose
to discharge or 12-hours post final IV opoid)
Secondary efficacy outcome: number of m Eq/kg body weight (IV and oral) adminis-
tered.
Participant-reported outcomes: HRQoL (measured by PedsQL™ generic core scales,
Sickle Cell Diseasemodule and fatiguemodule); days of schoolmissed; days of continued
pain; days of work missed (for parents)
Safety outcome measures: hypotension; weakness and warm sensation associated with
infusions; re-hospitalisation; Mg toxicity (serum levels). Used MedDRA classification
for adverse events
HRQoL assessed at enrolment, time of last study medication, 1 week post-discharge and
3 - 4 months post-discharge. Short-term outcomes assessed at 1 week post-discharge.
Blood samples taken prior to first infusion, 1 hour after start of 4th infusion and 1 - 3
months post-discharge
Notes InBrandow study (secondary data analysis ofMAGiC study), all participants additionally
received standard therapy for VOC in emergency department and during hospital stay,
other SCD-specific medications administered at discretion of blinded treating physician.
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Brousseau 2015 (Continued)
The mean total initial dose of opoid was 0.043 (0.029) mg/kg/hr; administered over a
median of 8.5 (IQR 6.4 -13.1) hours. The median time to first IV opoid was 1.02 (IQR
0.65 - 1.33) hours. The median time to first oral opioid was 28.3 (IQR 12.2 - 61.1)
hours. The opoids used were not separately mentioned either with Mg or placebo arm
ClinicalTrials.gov identifier: NCT01197417. Magnesium in Sickle Cell Crisis (MAGiC)
study
Awaiting response from the authors to provide further details of missing data and results
of outcome measures
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomization tables were provided by the
data co-ordinating centre and used ran-
domly varying block sizes for equal alloca-
tion stratified by age group (4 - 11 years and
12 - 21 years), study site and hydroxyurea
use during past 3 months
Allocation concealment (selection bias) Low risk Central randomization service was used.
Randomization tables were provided by
PECARN data coordinating centres to the
study site research pharmacy where the
study drug was prepared according to the
assigned study arm
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: ”Double blind, placebo controlled
trial. Children randomized to placebo re-
ceived an equivalent volume (1 mL/kg) of
normal saline over 20 minutes.“
92% of children answered the question
related to blinding: 47% Mg group ver-
sus 21% placebo correctly identified their
treatment allocation, 53% Mg versus 79%
placebo guessed incorrectly or stated that
they did not know
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind, placebo-controlled study
but the method of blinding of outcome as-
sessment was not described. There was in-
sufficient information tomake a judgement
Incomplete outcome data (attrition bias)
All outcomes
Low risk The number of withdrawals was balanced
across intervention groups with similar rea-
sons (no outcome data). One participant in
the Mg group did not have base line hae-
moglobin values. One participant in the
placebo group did not have a hemoglobin
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Brousseau 2015 (Continued)
or white blood cell values
Selective reporting (reporting bias) Low risk Study prespecified outcomes of interest
were reported.
Other bias Unclear risk Blood Mg levels were not measured before
and after IV Mg therapy
The targeted sample size calculation for this
study was 104 per arm with a total of 208
(see history of changes on clinicaltrials.gov
for NCT01197417). In the full publica-
tion, 410 potential participants were ap-
proached and 208 were randomized
The number of enrolled participants de-
scribed in the secondary data analysis of
the MAGiC study by Brandow was a total
of 204 individuals and did not mentioned
separately which treatment arm they were
in (Mg arm or placebo arm)
CHAMPS 2011
Methods Prospective, randomized, double-blind, Phase II study.
Parallel factorial design with 4 arms (HC + Mg placebo, Mg + HC placebo, HC + Mg,
or HC placebo + Mg placebo)
Duration: 44 weeks.
Multicentre: 14 sites.
Location: USA.
Participants Informed consent at baseline evaluations.
Eligible participants: HbSC and at least 1 VOC in previous 12 months, but none within
the previous 4 weeks. 44 participants were randomized, 36 reached the primary end
point and 22 participants completed the full 44 weeks
Baseline: minimum 20 to maximum 23 (Mg group), minimum 19 to maximum 21
(placebo group)
Week 8: minimum 13 to maximum 17 (Mg group), minimum 17 to maximum 19
(placebo group)
Week 24: minimum 12 to maximum 13 (Mg group), minimum 13 to maximum 14
(placebo group)
Participants were evenly distributed across the 4 treatment groups with regard to baseline
characteristics including age, gender, HbF, and hyperdense cells (P = 0.13 - 0.68)
Age: mean (range) 13.6 (5 - 53) years (73% under 16 years of age)
Gender split: 57% male, 43% female.
Interventions 4 arms: HC +Mg placebo, Mg + HC placebo, HC + Mg, or HC placebo + Mg placebo
Mg pidolate 0.6 m Eq/kg/day. Oral Mg pidolate (1 mmol/ml) was formulated by
Xcelience (Tampa,FL, USA) along with an indistinguishable placebo liquid, and admin-
istered at a dose of 0.3 mmol/kg/d, twice daily
HC (and HC placebo) administered orally at a dose of 20 mg/kg/d
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CHAMPS 2011 (Continued)
Outcomes Primary outcome: to estimate the maximum tolerated dose of Mg pidolate in combina-
tion with HC
Seondary outcomes: toxicity of combination of HC with Mg pidolate; haematological
parameters; red cell metabolism
Measured at baseline and then at bi-weekly intervals for the first 8 weeks, then and
every 4 weeks for a total of 44 weeks. At each visit, an interim history was obtained and
standard blood counts were performed. Evaluations at baseline and weeks 8, 16, 24, and
44 weeks included measures of erythrocyte density, cation content, K-Cl co-transport,
Gardos channel activity, Na/Mg exchange, endothelial adhesion, HbF levels, and plasma
Mg
Notes ClinicalTrials.gov identifier: NCT00143572.
Although the original sample size calculations called for the randomization of 188 par-
ticipants across the 4 treatment groups, the study was closed early due to slow enrolment,
with 64 participants enrolled and 44 participants randomized
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quotes: ” ... due to small numbers within
strata, sequential allocation algorithm was
used (Pocock 1975).“
Allocation concealment (selection bias) Unclear risk There was insufficient information tomake
a judgement.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind.
Masking: double-blind (participant, care-
giver, investigator, outcome assessor).
Placebo described as being indistinguish-
able from study medication
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Study was described as double blind (par-
ticipant, caregiver, investigator, outcome
assessor); however, the method of blinding
was not described. There was insufficient
information to make a judgement
Incomplete outcome data (attrition bias)
All outcomes
High risk 64 participants enrolled and 44 partici-
pants randomized, 36 participants com-
pleted 8 weeks of the study and only 22
participants completed the full 44 weeks
providing data for the primary end point
Selective reporting (reporting bias) Low risk Prespecified outcome measures from clini-
cal trials.gov: NCT00532883
Primary outcome: distribution of density
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CHAMPS 2011 (Continued)
of HbSC red cells.
Secondary outcomes: to determine the ef-
fects of Mg on hematological parameters
and toxicity
Other bias High risk The original sample size calculation was
188 participants across four treatment
arms, but only 44 people were randomized
before the study was terminated early be-
cause of the slow enrolment. In the full pa-
per, Wang states that 64 participants en-
rolled and 44 of these were randomized;
a total of 36 participants completed the
eight weeks of study (the primary end point
evaluation), but only 22 participants com-
pleted 44 weeks of treatment
De Montalembert 2003
Methods Randomized, double-blind, placebo-controlled, cross-over study with 2 arms
Duration: 6 months of Mg pidolate followed by 3-month washout period and 6 months
of placebo (or treatment in reverse order)
Location: Europe.
Participants 24 children with SCD suffering at least 1 painful crisis per year
Age: mean (SD) 9 (4) years, range 3 - 18 years.
Gender split: 17 male, 7 female.
Baseline weight: > 15 kg.
Interventions Intervention: oral Mg pidolate in blisters containing 1500 mg of pyrolidone carboxylate
of Mg per blister in following doses:
Weight 15 - 25 kg: 1 blister per day;
Weight 25 - 40 kg: 2 blisters per day;
Weight 40 - 55 kg: 3 blisters per day;
Weight > 55 kg: 4 blisters per day.
Control: placebo (no further details given).
Outcomes Number of painful days.
RBC Mg.
Plasma Mg.
Amount of analgesic administered.
Pain intensity measured by visual analogue scale.
Notes The study authors were asked to provide results of outcomes measured
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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De Montalembert 2003 (Continued)
Random sequence generation (selection
bias)
Low risk Quote (from report) ”Patients were ran-
domly allocated to one of the two arms :
6 months of Mg pidolate followed by 6
months of placebo, or treatment in the re-
verse order“
Quote (from correspondence): ”Treat-
ments were allocated by a central random-
ization service“
Allocation concealment (selection bias) Low risk There was insufficient information tomake
a judgement in the abstract but study au-
thors confirmed that treatments were allo-
cated by a central randomization service
Quote (from correspondent): ”Treatments
were allocated by a central randomization
service“
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No details or description of placebo given
in the abstract to allow us to make a clear
judgement but the lead author confirmed
that there was a full blinding of participants
and personnel as treatment and placebo
were not distinguishable
Quote (from correspondent): ”There was a
full blinding of participants and personnel“
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Study was described as double-blind and
placebo-controlled; however, the method
of blinding was not described
Quote (from correspondent): ”There was a
full blinding of participants and personnel“
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote ”Twenty-four children (17M, 7G)
mean age 9±4 years were included“
Comments: in the abstract there was no
mention of the number randomized or if
there were any withdrawals, but the lead
author confirmed that 24 participants were
randomized and there were no withdrawals
Selective reporting (reporting bias) Unclear risk The study protocol was not available.
Other bias Unclear risk Not clear if a sample size calculation was
undertaken.
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Goldman 2013
Methods Randomized, double-blind, placebo-controlled parallel study with 2 arms
Single centre (emergency department).
Location: Toronto, Canada.
Participants Total of 159 children approached for study. 106 children (67%) consented and were
randomized
2 (2%) withdrew consent. 104 children were included and analysed: 51 in Mg group,
53 in placebo group
Age: mean (SD) 12.4 (3.8) years, range 4 - 18 years.
Gender split: 56 (54%) female.
Disease status: 61 (58.6%) had homozygous sickle cell anaemia; 33 (31.7%) had sickle
haemoglobin C disease; 10 (9.6%) had sickle beta thalassaemia
Pain started a median of 24 hours before arrival at hospital (range 4 - 240 hours; SD 37
hours)
Elapsed time from last visit to emergency department until study admission (mean of 7.
3 months in MgSO4 group and 8.7 months in placebo group)
Interventions Intervention: IV MgSO4 (100 mg/kg, maximum of 2 g per dose) every 8 hours until
deemed ready for discharge
Control: IV placebo (normal saline in volume equivalent toMgSO4) every 8 hours until
deemed ready for discharge
Outcomes LOS in hospital.
Mean daily pain intensity.
Cumulative analgesic dose required during admission.
Adverse events (changes in vital signs, appearance of rash, allergic reactions, diarrhoea,
fever, nausea, vomiting, pain at infusion site)
Notes Clinical trial.gov identifier: NCT00313963 (MAST study)
There were differences in the earlier published paper from 2011
In Goldman 2011, 107 participants were randomized and 104 included
LOS was 82.4 hours in Mg group and 79.3 hours in placebo group (P = 0.52)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote ”Randomisation and dispensing
were conducted by research pharmacy us-
ing a preset randomisation table (blocks of
4)“
Study design was mentioned as 2-armed
randomized, double-blind, placebo-con-
trolled study. Participants with families
providing consent were randomly assigned
Allocation concealment (selection bias) Low risk Quote ”Families providing consent were
randomly assigned by research pharmacist
to receive IV MgSO4 100mg/kg, maxi-
41Magnesium for treating sickle cell disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Goldman 2013 (Continued)
mum of 2 g dose) 8 hourly or IV placebo..
.....“
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote ”Investigators, physicians, nurses,
parents, patients were blinded to the treat-
ment arm. Study drug and placebo looked
exactly the same (volume and appearance)
“
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote ”Invstigators, physicians, nurses,
parents, patients were blinded to the treat-
ment arm.“
Comment: insufficient information to
make a judgement.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote ”106 consented, two children (2%)
withdrew from the study because of with-
drawal of consent. A total of 98 unique pa-
tients who had 104 episodes in which they
were recruited to the study“
Selective reporting (reporting bias) Low risk Pre-specified outcomes were reported.
Other bias High risk The targeted sample size expected from
protocol was not achieved. A total of 159
individuals were approached to participate,
106 consented and 2 participants later
withdrew their consent
The abstract published in 2011 stated that
107 were randomized and 106 children
were included
Mueller 2005
Methods Randomized controlled cross-over study with 2 arms.
Duration: 16 months in total (oral Mg pidolate or placebo for 6 months, followed by 2-
month washout period, then cross over to 6 months period of alternate agent (placebo/
Mg) and 2 months wash out)
Multicentre: 2 major paediatric sickle cell centres.
Location: Boston and Texas, USA.
Participants Over 100 children invited to participate between January 2002 and December 2004,
enrolled participants or parents/guardian gave informed consent. Only 12 participants
with HbSC disease and at least 1 pain crisis within last year were enrolled
Age: range 3.9 to 16.8 years.
Gender split: 7 male, 5 female.
Of 12 participants, 5 were evaluated for efficacy assessment, 7 dropped out of trial for
several reasons: 3 for non-compliance, 2 for study violation (pharmacy dispense wrong
formulation), 2 withdrew for personal reasons
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Mueller 2005 (Continued)
Interventions Intervention: a liquid containing 0.6mEqMg pidolate/kg/body weight per day, divided
into 2 daily doses; Mg pidolate (45 g) distributed as a pre-mixed powder containing
Koolaid Tropical Punch powder (9 g), and sucrose (67 g)
Control: a placebo liquid containing an equivalent amount of placebo to the study
medication, divided into 2 daily doses; contained the same amount of sucrose and
Tropical Punch powder as the intervention as well as 45 g of lactose
Outcomes Primary outcome: change in the number of painful crises.
Secondary outcomes: tolerance of long-term treatment with oral Mg pidolate; change
in the intracellular Mg content of erythrocytes; effect of Mg pidolate therapy on the K-
Cl co transport system activity
Follow-up undertaken every 2 weeks, then every 4 weeks.
Notes Clinical trials.gov identifier: NCT00040456
The study was terminated due to poor participant enrolment.
The study was opened to 2 major sickle cell centres and had relatively non-restrictive
enrolment criteria, accrual was extremely low, presumably due to sporadic and rather
low disease intensity of HbSC disease
We have requested further details from the study investigators (randomization, blinding,
missing data and efficacy results of outcomes measure)
Abstract was published 10 years ago and a search using authors’ name did not reveal full
publication; to date no data received from study investigators
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomized, but no details
given for how the sequence was generated.
Insufficient information to judge
Allocation concealment (selection bias) Unclear risk Insufficient information to judge.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Entry on clinicaltrials.gov NCT00040456
states there was double-blindmasking (par-
ticipant, caregiver, investigator). Placebo
described as a liquid containing an equiva-
lent amount of placebo to the study med-
ication, divided into the same number
of daily doses and containing the same
amount of sucrose and Tropical Punch
powder as the intervention as well as 45 g
of lactose
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Entry on clinicaltrials.gov NCT00040456
states there was double-blindmasking (par-
ticipant, caregiver, investigator); however,
the method of blinding the outcome asses-
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Mueller 2005 (Continued)
sors was not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Of 12 participants, 5 were evaluated for ef-
ficacy assessment, 7 dropped out of trial for
several reasons: 3 for non-compliance, 2 for
study violation (pharmacy dispense wrong
formulation), 2 withdrew for personal rea-
sons
Selective reporting (reporting bias) Unclear risk There was insufficient information to
judge.
Other bias Unclear risk In this study expected to enrol 20 partic-
ipants; 100 eligible potential participants
were contacted and invited to participate in
the study. According to the current recruit-
ing status on clinicaltrials.gov, the number
of participants recruited is 12 and the study
was terminated due to lack of accrual. A
full paper has not been published and the
results for 12 participants have only been
presented narratively without data analyses
HbF: foetal haemoglobin
HbSC: haemoglobin sickle cell
HC: hydroxyurea
HRQoL: health-related quality of life
IQR: interquartile range
IV: intravenous
LOS: length of stay
m Eq: morphine equivalent units
Mg: magnesium
MgSO4: magnesium sulphate
Na: sodium
RBC: red blood cell
SCD: sickle cell disease
SD: standard deviation
VOC: vaso-occlusive crisis
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Brousseau 2004 A prospective, non-randomized and non-blinded, single-arm convenience sample, with historical controls
De Franceschi 1997 A pilot study with 10 participants, not a randomized controlled study
De Franceschi 2000 Open-label unblinded study with no control group (all participants received magnesium pidolate)
Hankins 2007 A phase I dose-escalation pilot study of magnesium in combination with hydroxyurea not magnesium alone;
no placebo or no magnesium comparator
Characteristics of studies awaiting assessment [ordered by study ID]
Voskaridou 2000
Methods Placebo-controlled clinical study.
Duration: 6 months.
Participants 10 adults with HbS/b thalassaemia.
Interventions Intervention (n = 5): 0.6 m Eq/kg/day oral Mg aspartate.
Control (n = 5): placebo.
Outcomes Red blood cell Mg.
Red cell distribution width.
Dense red cells.
Mean corpuscular haemoglobin concentration and reticulocytes
Frequency of crisis.
Notes Awaiting response from the authors to request to provide further details about randomizations, blinding and outcomes
measured
Two abstracts published 15 years ago (1999 and 2000) with no further published paper available
m Eq: morphine equivalent units
Mg: magnesium
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D A T A A N D A N A L Y S E S
Comparison 1. Intravenous magnesium sulphate versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain score 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Up to 1 month 1 104 Mean Difference (IV, Fixed, 95% CI) 0.10 [-0.82, 1.02]
2 Quality of Life (Child self-report
total score)
1 Mean Difference (Fixed, 95% CI) Subtotals only
2.1 Child self-reported
PedsQL Generic Scales
(Pre-discharge)
1 173 Mean Difference (Fixed, 95% CI) 1.5 [-37.50, 40.50]
2.2 Child self-reported
PedsQL Generic Scales (1 week
follow-up)
1 161 Mean Difference (Fixed, 95% CI) -2.3 [-7.21, 2.61]
2.3 Child self-reported
PedsQL Multidimensional
Fatigue Scales (Pre-discharge)
1 175 Mean Difference (Fixed, 95% CI) 2.8 [-2.06, 7.66]
2.4 Child self-reported
PedsQL Multidimensional
Fatigue Scales (1 week
follow-up)
1 160 Mean Difference (Fixed, 95% CI) -1.4 [-13.44, 10.64]
2.5 Child self-reported
PedsQL Sickle Cell Disease
Module (Pre-discharge)
1 179 Mean Difference (Fixed, 95% CI) -3.20 [-7.75, 1.35]
2.6 Child self-reported
PedsQL Sickle Cell Disease
Module (1 week follow-up)
1 160 Mean Difference (Fixed, 95% CI) -3.5 [-14.95, 7.95]
3 Quality of Life (Parent self-report
total score)
1 Mean Difference (Fixed, 95% CI) Subtotals only
3.1 Parent self-reported
PedsQL Generic Scales
(Pre-discharge)
1 146 Mean Difference (Fixed, 95% CI) -5.4 [-12.17, 1.37]
3.2 Parent self-reported
PedsQL Generic Scales (1 week
follow-up)
1 142 Mean Difference (Fixed, 95% CI) -2.0 [-6.85, 2.85]
3.3 Parent self-reported
PedsQL Multidimensional
Fatigue Scales (Pre-discharge)
1 148 Mean Difference (Fixed, 95% CI) -2.7 [-7.79, 2.39]
3.4 Parent self-reported
PedsQL Multidimensional
Fatigue Scales (1 week
follow-up)
1 143 Mean Difference (Fixed, 95% CI) -0.5 [-2.87, 1.87]
3.5 Parent self-reported
PedsQL Sickle Cell Disease
Module (Pre-discharge)
1 150 Mean Difference (Fixed, 95% CI) -2.4 [-4.88, 0.08]
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3.6 Parent self-reported
PedsQL Sickle Cell Disease
Module (1 week follow-up)
1 74 Mean Difference (Fixed, 95% CI) -0.4 [-1.85, 1.05]
4 Length of hospital stay (hours) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 Up to 1 month 1 104 Mean Difference (IV, Fixed, 95% CI) 14.70 [-20.51, 49.
91]
5 Adverse effects (at up to 1
month)
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Nausea or vomiting 1 104 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.15, 7.10]
5.2 Hypotension 2 306 Risk Ratio (M-H, Fixed, 95% CI) 2.57 [0.50, 13.08]
5.3 Pain at the infusion site 1 104 Risk Ratio (M-H, Fixed, 95% CI) 3.64 [0.79, 16.69]
5.4 Warmth at the infusion
site
1 202 Risk Ratio (M-H, Fixed, 95% CI) 13.26 [3.23, 54.40]
5.5 Pruritus 1 104 Risk Ratio (M-H, Fixed, 95% CI) 0.35 [0.01, 8.31]
5.6 Tachycardia 1 104 Risk Ratio (M-H, Fixed, 95% CI) 0.35 [0.01, 8.31]
5.7 Drowsiness 1 104 Risk Ratio (M-H, Fixed, 95% CI) 3.12 [0.13, 74.76]
5.8 Acute chest syndrome 1 202 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.60, 2.26]
Comparison 2. Oral magnesium pidolate versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain diary of days with
significant pain
1 Mean Difference (Fixed, 95% CI) Totals not selected
2 Effects on magnesium content
(erythrocytes)
1 Mean Difference (Fixed, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 Intravenous magnesium sulphate versus placebo, Outcome 1 Pain score.
Review: Magnesium for treating sickle cell disease
Comparison: 1 Intravenous magnesium sulphate versus placebo
Outcome: 1 Pain score
Study or subgroup Magnesium sulphate Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 1 month
Goldman 2013 51 5.4 (2.5) 53 5.3 (2.3) 100.0 % 0.10 [ -0.82, 1.02 ]
Subtotal (95% CI) 51 53 100.0 % 0.10 [ -0.82, 1.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.83)
-1 -0.5 0 0.5 1
Favours Mg sulphate Favours placebo
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Analysis 1.2. Comparison 1 Intravenous magnesium sulphate versus placebo, Outcome 2 Quality of Life
(Child self-report total score).
Review: Magnesium for treating sickle cell disease
Comparison: 1 Intravenous magnesium sulphate versus placebo
Outcome: 2 Quality of Life (Child self-report total score)
Study or subgroup
Intravenous
Mg sulphate Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 Child self-reported PedsQL Generic Scales (Pre-discharge)
Brousseau 2015 84 89 1.5 (19.898913) 100.0 % 1.50 [ -37.50, 40.50 ]
Subtotal (95% CI) 84 89 100.0 % 1.50 [ -37.50, 40.50 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.94)
2 Child self-reported PedsQL Generic Scales (1 week follow-up)
Brousseau 2015 82 79 -2.3 (2.50539) 100.0 % -2.30 [ -7.21, 2.61 ]
Subtotal (95% CI) 82 79 100.0 % -2.30 [ -7.21, 2.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
3 Child self-reported PedsQL Multidimensional Fatigue Scales (Pre-discharge)
Brousseau 2015 85 90 2.8 (2.47766) 100.0 % 2.80 [ -2.06, 7.66 ]
Subtotal (95% CI) 85 90 100.0 % 2.80 [ -2.06, 7.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.13 (P = 0.26)
4 Child self-reported PedsQL Multidimensional Fatigue Scales (1 week follow-up)
Brousseau 2015 81 79 -1.4 (6.142398) 100.0 % -1.40 [ -13.44, 10.64 ]
Subtotal (95% CI) 81 79 100.0 % -1.40 [ -13.44, 10.64 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
5 Child self-reported PedsQL Sickle Cell Disease Module (Pre-discharge)
Brousseau 2015 87 92 -3.2 (2.3225179) 100.0 % -3.20 [ -7.75, 1.35 ]
Subtotal (95% CI) 87 92 100.0 % -3.20 [ -7.75, 1.35 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.38 (P = 0.17)
6 Child self-reported PedsQL Sickle Cell Disease Module (1 week follow-up)
Brousseau 2015 81 79 -3.5 (5.8426) 100.0 % -3.50 [ -14.95, 7.95 ]
-20 -10 0 10 20
Favours placebo Favours IV Mg sulphate
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(. . . Continued)
Study or subgroup
Intravenous
Mg sulphate Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
Subtotal (95% CI) 81 79 100.0 % -3.50 [ -14.95, 7.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
-20 -10 0 10 20
Favours placebo Favours IV Mg sulphate
Analysis 1.3. Comparison 1 Intravenous magnesium sulphate versus placebo, Outcome 3 Quality of Life
(Parent self-report total score).
Review: Magnesium for treating sickle cell disease
Comparison: 1 Intravenous magnesium sulphate versus placebo
Outcome: 3 Quality of Life (Parent self-report total score)
Study or subgroup IV Mg sulphate Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 Parent self-reported PedsQL Generic Scales (Pre-discharge)
Brousseau 2015 75 71 -5.4 (3.45256) 100.0 % -5.40 [ -12.17, 1.37 ]
Subtotal (95% CI) 75 71 100.0 % -5.40 [ -12.17, 1.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.56 (P = 0.12)
2 Parent self-reported PedsQL Generic Scales (1 week follow-up)
Brousseau 2015 75 67 -2 (2.47278) 100.0 % -2.00 [ -6.85, 2.85 ]
Subtotal (95% CI) 75 67 100.0 % -2.00 [ -6.85, 2.85 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.81 (P = 0.42)
3 Parent self-reported PedsQL Multidimensional Fatigue Scales (Pre-discharge)
Brousseau 2015 77 71 -2.7 (2.595834) 100.0 % -2.70 [ -7.79, 2.39 ]
Subtotal (95% CI) 77 71 100.0 % -2.70 [ -7.79, 2.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
4 Parent self-reported PedsQL Multidimensional Fatigue Scales (1 week follow-up)
-10 -5 0 5 10
Favours placebo Favours IV Mg sulphate
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(. . . Continued)
Study or subgroup IV Mg sulphate Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
Brousseau 2015 75 68 -0.5 (1.2097) 100.0 % -0.50 [ -2.87, 1.87 ]
Subtotal (95% CI) 75 68 100.0 % -0.50 [ -2.87, 1.87 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
5 Parent self-reported PedsQL Sickle Cell Disease Module (Pre-discharge)
Brousseau 2015 77 73 -2.4 (1.26627) 100.0 % -2.40 [ -4.88, 0.08 ]
Subtotal (95% CI) 77 73 100.0 % -2.40 [ -4.88, 0.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.90 (P = 0.058)
6 Parent self-reported PedsQL Sickle Cell Disease Module (1 week follow-up)
Brousseau 2015 74 0 -0.4 (0.74063) 100.0 % -0.40 [ -1.85, 1.05 ]
Subtotal (95% CI) 74 0 100.0 % -0.40 [ -1.85, 1.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
-10 -5 0 5 10
Favours placebo Favours IV Mg sulphate
Analysis 1.4. Comparison 1 Intravenous magnesium sulphate versus placebo, Outcome 4 Length of hospital
stay (hours).
Review: Magnesium for treating sickle cell disease
Comparison: 1 Intravenous magnesium sulphate versus placebo
Outcome: 4 Length of hospital stay (hours)
Study or subgroup Magnesium sulphate Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 1 month
Goldman 2013 51 132.6 (106.6) 53 117.9 (72.8) 100.0 % 14.70 [ -20.51, 49.91 ]
Subtotal (95% CI) 51 53 100.0 % 14.70 [ -20.51, 49.91 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
-200 -100 0 100 200
Favours Mg sulphate Favours placebo
50Magnesium for treating sickle cell disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.5. Comparison 1 Intravenous magnesium sulphate versus placebo, Outcome 5 Adverse effects
(at up to 1 month).
Review: Magnesium for treating sickle cell disease
Comparison: 1 Intravenous magnesium sulphate versus placebo
Outcome: 5 Adverse effects (at up to 1 month)
Study or subgroup Magnesium sulphate Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Nausea or vomiting
Goldman 2013 2/51 2/53 100.0 % 1.04 [ 0.15, 7.10 ]
Subtotal (95% CI) 51 53 100.0 % 1.04 [ 0.15, 7.10 ]
Total events: 2 (Magnesium sulphate), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
2 Hypotension
Goldman 2013 1/51 1/53 49.8 % 1.04 [ 0.07, 16.18 ]
Brousseau 2015 4/100 1/102 50.2 % 4.08 [ 0.46, 35.87 ]
Subtotal (95% CI) 151 155 100.0 % 2.57 [ 0.50, 13.08 ]
Total events: 5 (Magnesium sulphate), 2 (Placebo)
Heterogeneity: Chi2 = 0.59, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 1.13 (P = 0.26)
3 Pain at the infusion site
Goldman 2013 7/51 2/53 100.0 % 3.64 [ 0.79, 16.69 ]
Subtotal (95% CI) 51 53 100.0 % 3.64 [ 0.79, 16.69 ]
Total events: 7 (Magnesium sulphate), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.66 (P = 0.097)
4 Warmth at the infusion site
Brousseau 2015 26/100 2/102 100.0 % 13.26 [ 3.23, 54.40 ]
Subtotal (95% CI) 100 102 100.0 % 13.26 [ 3.23, 54.40 ]
Total events: 26 (Magnesium sulphate), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.59 (P = 0.00033)
5 Pruritus
Goldman 2013 0/51 1/53 100.0 % 0.35 [ 0.01, 8.31 ]
0.01 0.1 1 10 100
Favours Mg sulphate Favours placebo
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(. . . Continued)
Study or subgroup Magnesium sulphate Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 51 53 100.0 % 0.35 [ 0.01, 8.31 ]
Total events: 0 (Magnesium sulphate), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.51)
6 Tachycardia
Goldman 2013 0/51 1/53 100.0 % 0.35 [ 0.01, 8.31 ]
Subtotal (95% CI) 51 53 100.0 % 0.35 [ 0.01, 8.31 ]
Total events: 0 (Magnesium sulphate), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.51)
7 Drowsiness
Goldman 2013 1/51 0/53 100.0 % 3.12 [ 0.13, 74.76 ]
Subtotal (95% CI) 51 53 100.0 % 3.12 [ 0.13, 74.76 ]
Total events: 1 (Magnesium sulphate), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
8 Acute chest syndrome
Brousseau 2015 16/100 14/102 100.0 % 1.17 [ 0.60, 2.26 ]
Subtotal (95% CI) 100 102 100.0 % 1.17 [ 0.60, 2.26 ]
Total events: 16 (Magnesium sulphate), 14 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
0.01 0.1 1 10 100
Favours Mg sulphate Favours placebo
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Analysis 2.1. Comparison 2 Oral magnesium pidolate versus placebo, Outcome 1 Pain diary of days with
significant pain.
Review: Magnesium for treating sickle cell disease
Comparison: 2 Oral magnesium pidolate versus placebo
Outcome: 1 Pain diary of days with significant pain
Study or subgroup Magnesium pidolate Placebo Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
De Montalembert 2003 24 24 1.9 (1.50499) 1.90 [ -1.05, 4.85 ]
-10 -5 0 5 10
Favours placebo Favours Mg pidolate
Analysis 2.2. Comparison 2 Oral magnesium pidolate versus placebo, Outcome 2 Effects on magnesium
content (erythrocytes).
Review: Magnesium for treating sickle cell disease
Comparison: 2 Oral magnesium pidolate versus placebo
Outcome: 2 Effects on magnesium content (erythrocytes)
Study or subgroup Magnesium pidolate Placebo Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
De Montalembert 2003 24 24 0.46 (0.3809) 0.46 [ -0.29, 1.21 ]
-4 -2 0 2 4
Favours placebo Favours Mg pidolate
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A D D I T I O N A L T A B L E S
Table 1. Length of stay (hours)
Study: Brousseau 2015 Magnesium Group Placebo Group P value
LOS: median (IQR) 56.0 (27.0 - 109.0) 47.0 (24.0 - 99.0) P = 0.24
LOS: total time until discharge
from hospital
74.5 (40.0 - 124.0) 60.5 (37.0 - 122.0) P = 0.46
LOS: early in the course of the
pain crisis
58.0 (30.0 - 113.0) 47.0 (23.0 - 92.5) P = 0.49
IQR: interquartile range
LOS: length of stay
Table 2. Effects on K-Cl cotransport, red cell K+ and Mg2+ content
Study:
CHAMPS 2011
Ion content
Mg No Mg
N (minimum, maximum) N (minimum, maximum)
(20, 23) (13, 17) (12, 13) (19, 21) (17, 19) (13, 14)
Baseline Week 8 Week 24 Baseline Week 8 Week 24
Plasma ionized
Mg (mmol/l)
0.57 0.62 0.58 0.59 0.59 0.57
Plasma total Mg
(mmol/L)
0.85 0.90 0.87 0.87 0.86 0.84
K-Cl co-trans-
port (mmol/10
13cells x h)
13.3 13.6 13.9 13.1 14.9 13.1
Cell Na (mmol/
kg Hb)
43.5 48.6 43.7 39.6 41.2 40.2
Cell K (mmol/kg
Hb)
229 233 223 232 236 236
Both mean levels of plasma ionised Mg and plasma total Mg at week 8 were slightly greater compared to placebo (P value = 0.02 for
ionised Mg) (P value = 0.04 for total Mg).
Cl: chloride
Hb: haemoglobin
K: potassium
Mg: magnesium
Na: sodium
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A P P E N D I C E S
Appendix 1. Electronic search strategies
Database/Resource Strategy
PubMed (1946 to date)
Date of search: 01 April 2017
(magnesium OR mgS04) AND sickle
Clinicaltrials.gov
Date of search: 29 March 2017
SEARCH 1: magnesium AND sickle
SEARCH 2: mgS04 AND sickle
WHO ICTRP
Date of search: 29 March 2017
SEARCH 1: magnesium AND sickle
SEARCH 2: mgS04 AND sickle
ISRCTN Registry
Date of search: 29 March 2017
SEARCH 1: magnesium AND sickle
SEARCH 2: mgS04 AND sickle
C O N T R I B U T I O N S O F A U T H O R S
Roles and responsibilities Roles and responsibilities
Task Who will undertake the task?
Protocol stage: draft the protocol NNT, HHKS,SK, ALA
Review stage: select which trials to include (2 + 1 arbiter) NNT, HHKS, ALA
Review stage: extract data from trials (2 people) NNT, HHKS
Review stage: enter data into RevMan NNT,SK, ALA
Review stage: carry out the analysis NNT, HHKS, SK, LDF
Review stage: interpret the analysis NNT, HHKS, ALA, LDF
Review stage: draft the final review NNT, ALA, SK, LDF
Update stage: update the review NNT, HHKS, SK, ALA, LDF
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D E C L A R A T I O N S O F I N T E R E S T
All authors: none known.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• National Institute for Health Research, UK.
This systematic review was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the
Cochrane Cystic Fibrosis and Genetic Disorders Group.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In a post hoc change we included two summary of findings tables for the comparison of oral and intravenous magnesium sulphate
versus placebo. We also presented the adverse events outcome in general instead of classified into mild, moderate, severe.
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